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ABSTRACT: 
This thesis investigates the biopharmaceutical knowledge of different liposomal formulations using 
two different phosphatidylcholines (EPC and S 90) in the presence and absence of gelatine. The 
study aimed to characterize the oral lipid-based formulations in terms of physiochemical features, 
X-ray diffraction, dissolution, in vitro lipolysis and in vivo pharmacokinetic studies.  
The prepared liposomes were used to investigate the physical features of vesicular phospholipid 
gels (VPGs) and the light-scattering assessed the size and polydispersity of the liposomes. 
Fenofibrate-loaded liposomes had remarkably high entrapment efficiency (95%–99%). The 
dissolution behaviour of the samples was evaluated in a paddle model and the results showed a 
negative correlation between the rate of liposome release and gelatine concentration. The prepared 
liposomes were used in a dynamic in vitro lipolysis model to study the digestion and solubilisation 
of the drug formulations in biorelevant media simulating the gastrointestinal environment. The 
release profile of fenofibrate for all liposomal formulations showed a general increasing trend 
(regardless of the type of phosphatidylcholine and amount of gelatine) towards the release of 
fenofibrate from the formulations in the aqueous phase. For the in vivo studies, EPC and S 90 
liposomes were administered orally to fasted rats for pharmacokinetic characterization. The in vivo 
studies demonstrated that Soluthin S 90 formulations, regardless of the presence or absence of 
gelatine, showed significantly higher (p<0.01) pharmacokinetic parameters in terms of AUC and 
Cmax. All formulations showed a similar Tmax, and the presence or absence of gelatine had no 
significant effect on AUC, Cmax or Tmax for both EPC- and Soluthin S 90-type liposomal 
formulations.  
In this study, the absence and presence of gelatine in the in vitro rat lipolysis model correlated with 
the results of the in vivo pharmacokinetic studies, and the data from the NaOH titration, 
corresponding with the digestion and FA release, virtually correlated with the in vivo plasma 
concentration. However, in term of the drug solubilisation profile, no significant correlation was 
observed between the in vitro and in vivo studies, particularly in the case of the in vitro lipolysis 
model.  
In conclusion, the addition of gelatine did not have a significant effect on pharmacokinetic 
parameters. The new phosphatidylcholine mixture, Soluthin S 90, strongly improved the absorption 
and bioavailability of fenofibrate-loaded liposomes. Further studies should be performed to 
investigate the effect of fenofibrate-loaded liposomes prepared by Soluthin S 90 on the intestinal 
permeability of the API and solubilisation capacity of the formulations in an in vitro lipolysis model 
combined with an absorption step. It is also recommended to combine the formulation with 
different surfactants to choose the optimal formulation. In addition, it is necessary to examine the 
bioavailability of different poorly water-soluble drugs (PWSDs) formulated in Soluthin S 90 
liposomes to elucidate the pharmacokinetic effect of such a formulation.  
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ZUSAMMENFASSUNG 
Diese Arbeit untersucht das biopharmazeutische Verhalten verschiedener liposomaler 
Formulierungen, die mit zwei verschiedenen Phosphatidylcholinen (EPC und S 90) in Gegenwart 
und Abwesenheit von Gelatine erhalten wurden. Ziel der Studie war es, die oralen Formulierungen 
auf Lipidbasis in Bezug auf physiochemische Eigenschaften, Röntgenbeugung, Auflösung, in vitro 
Lipolyse und in vivo Pharmakokinetik zu charakterisieren. 
Die hergestellten Liposomen wurden verwendet, um die physikalischen Eigenschaften von 
vesikulären Phospholipidgelen (VPGs) zu untersuchen, wobei die Größe und Polydispersität der 
Liposomen mittels Lichtstreuung beurteilt wurden. Fenofibrat-beladene Liposomen hatten eine 
bemerkenswert hohe Einschlusswirksamkeit (95% -99%). Das Auflösungsverhalten der Proben 
wurde in einem Paddelmodell ausgewertet und die Ergebnisse zeigten eine negative Korrelation 
zwischen der Rate der Liposomfreisetzung und der Gelatinekonzentration. Die hergestellten 
Liposomen wurden in einem dynamischen in vitro-Lipolyse-Modell verwendet, um die Verdauung 
und Solubilisierung der Arzneimittelformulierungen in biorelevanten Medien zu untersuchen, die 
die gastrointestinale Umgebung simulieren. Das Freisetzungsprofil von Fenofibrat für alle 
liposomalen Formulierungen zeigte einen allgemeinen zunehmenden Trend (unabhängig von der 
Art des Phosphatidylcholins und der Gelatinemenge) gegenüber der Freisetzung von Fenofibrat aus 
den Formulierungen in der wässrigen Phase. Für die in vivo-Studien wurden EPC- und S 90 -
Liposomen oral an nüchterne Ratten zur pharmakokinetischen Charakterisierung verabreicht. Die in 
vivo-Studien zeigten, dass Soluthin S 90 - Formulierungen unabhängig von der Anwesenheit oder 
Abwesenheit von Gelatine signifikant höhere (p <0,01) pharmakokinetische Parameter in Bezug auf 
AUC und Cmax zeigten. Alle Formulierungen zeigten eine ähnliche Tmax, und die Anwesenheit oder 
Abwesenheit von Gelatine hatte keine signifikante Wirkung auf AUC, Cmax oder Tmax für sowohl 
EPC- als auch Soluthin S 90-liposomale Formulierungen.  
In dieser Studie korrelierte das Fehlen und Vorhandensein von Gelatine im in vitro-Lipolyse- 
Modell mit den Ergebnissen der pharmakokinetischen in-vivo-Studien, und die Daten der NaOH-
Titration, die der Verdauung und der FA-Freisetzung entsprachen, korrelierten praktisch mit denen 
in vivo Plasmakonzentration. Im Hinblick auf das Arzneimittelsolubilisierungsprofil wurde jedoch 
keine signifikante Korrelation zwischen den in vitro- und in vivo Studien beobachtet, insbesondere 
im Falle des in vitro Lipolyse-Modells.  
Zusammenfassend hat die Zugabe von Gelatine keinen signifikanten Effekt auf die 
pharmakokinetischen Parameter. Das Phosphatidylcholin-Gemisch, Soluthin S 90, verbesserte die 
Absorption und Bioverfügbarkeit von Fenofibrat-beladenen Liposomen stark. Weitere Studien 
sollten durchgeführt werden, um die Wirkung von Fenofibrat-beladenen Liposomen, hergestellt 
durch Soluthin S 90, auf die intestinale Permeabilität der API und die Solubilisierungskapazität der 
Formulierungen in einem in vitro-Lipolyse-Modell, kombiniert mit einem Absorptionsschritt, zu 
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untersuchen. Es wird auch empfohlen, die Formulierung mit verschiedenen Tensiden zu 
kombinieren, um die optimale Formulierung zu wählen. Darüber hinaus ist es notwendig, die 
Bioverfügbarkeit verschiedenen schlecht wasserlöslichen Arzneimitteln (PWSDs) zu untersuchen, 
die in in Soluthin S 90-Liposomen formulierter, um die Pharmakokinetik Effekt einer solchen 
Formulierung aufzuklären.   
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1. INTRODUCTION
  
2 
  
 
 
1.1 Oral Drug Delivery 
There are different routes for drug administration, for instance parenteral, nasal, inhalation and 
transdermal, but by far the most convenient route is the oral administration for systemic purposes. 
The very early question being asked in pharmaceutical companies after the discovery of an Active 
Pharmaceutical Ingredient (API) is whether or not it could be orally applied. Oral drug delivery 
(ODD), one of the oldest drug deliveries is applied for a large number of therapeutic drugs available 
in the market. as it is low-cost, non-invasive, convenient to use, higher compliance and in terms of 
the dosage form is flexible, accurate and also measurable. Besides these advantages, for oral drug 
administrations the main issue is to overcome. the harsh condition of the gastrointestinal and have a 
successful effect and this mainly is mainly influenced by on the nature of drug compound and the 
type of formulation. 
About 40% of the new chemical entities (NCEs) from the industrial drug discovery processes. 
exhibit poor water solubility and low bioavailability after oral administration (BCS II or IV drugs), 
which take time and cost a lot to pass the phases after drug discovery (clinical testing, development, 
and regulatory) (Hite, M., Turner, S., Federici 2003). Many of these new drugs fail in clinical. 
assessments due to the problem of water solubility, even though they showed a very strong treating 
effect in pharmacological terms. Furthermore, many existing drugs available on the market still face 
the problem of poor water solubility. The solubility in water of a drug is critical as it shows the 
solubility in the aqueous gastrointestinal (GI) fluids. Poor water solubility. Strongly decreases the 
absorption. from GI tract resulting in a poor oral bioavailability (Rinaki et al. 2003). 
More than finding an appropriate oral formulation for recently discovered APIs, most of the 
pharmaceutical companies have been encouraged to reformulate. the drugs and improve their 
medical effects. The different novel technologies for oral drug delivery are challenging the market 
situation. The companies are paying a lot of attention to reformulations as there are many advanced 
technologies, which control the release rate and bioavailability (Kalepu & Nekkanti 2015). The new 
novel oral delivery technologies can improve the efficacy by showing a better pharmacological. 
result with the same quantity of the drug, which decreases the cost of manufacturing as well as the 
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cost of therapy to the patient and, therefore, increase the patient compliance. These technologies 
provide benefits for both pharma companies and patients. 
It is very important for pharmaceutical companies to increase the compliance of patients since many 
patients are not going to the treatment regime due to the difficulty of administration or the 
unpleasant taste of a drug. It is also very critical for companies to find a convenient administration 
for a drug. A study in the USA by the New England Healthcare Institute (NEHI) revealed. a very 
noticeable result in terms of non-compliance of the patients. It has shown that the cost of non-
compliance to medicines is about $290 billion just in the U.S. This hardly suggests pharma 
companies to increase the compliance rate in order to earn more financial benefits (Cutler & Everett 
2010).  
 
1.2 The Biopharmaceutics Classification System 
The Biopharmaceutics Classification System (BCS) was first proposed by Amidon in 1995 
(Amidon et al. 1995). The BCS is a complimentary classification guideline to differentiate drug 
compounds according to their aqueous solubility and intestinal permeability. The aim of the 
system is to improve, simplify, and speed up the drug development process. There are three 
important factors rolling in the BCS guidance; solubility, dissolution, and intestinal permeability, 
which define the rate and amount of drug absorption (F. and D. Administration 1997). In the 
process of drug development, the concept of BCS provides a basis to predict about the in vivo 
pharmacokinetics of oral drug products and possess relationship between drug release and the 
absorption process (Sachan et al. 2009). The BCS classification consisted of four individual 
classes (Figure 1): 
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Figure 1. Biopharmaceutics Classification System classification (Rautio et al. 2008).  
 
Class I is ideal for oral drug delivery systems with a high solubility as well as high permeability. 
Drugs belonging. to this class dissolve easily in hydrophilic media and the absorption is expected to 
be high (Di & Kerns 2015). Class II contains drugs with a low solubility in water but a high 
intestinal permeability. In this category, the dissolution test is expected to be rate-limiting regarding 
absorption. Approximately 70% of new molecular entities are distributed in this class (Benet 2007). 
Drugs belonging to Class III possess high water solubility and a low permeability. through the 
intestinal wall. The permeability test is commonly used to predict the bioavailability of this drug 
group. Class IV drugs have a low solubility as well as a low permeability, which makes the 
development of these compounds risky and really costly (Kerns & Di 2008). 
Fenofibrate (FF), a highly lipophilic drug, is a BCS class-II drug and used widely as a 
hypolipidemic. agent to lower the risk caused by atherosclerosis. Fenofibrate as a poorly water-
soluble drug (PWSD) is mainly used to reduce cholesterol levels and like other fibrates, it reduces 
both low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) levels, as well as 
increasing high-density. lipoprotein (HDL) levels while reducing triglyceride (TG) levels. Due to 
the low water solubility of fenofibrate, dissolution is slow and, therefore, the oral bioavailability is 
limited (Zuo et al. 2013). Currently, different oral drug delivery systems have been developed to 
increase bioavailability. of FF, for instance, solid dispersion (Kawakami et al. 2013), a self-
microemulsifying drug delivery system (Patel & Vavia 2007), lipid-based formulations (Tian et al. 
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2013), nanocrystals (Zuo et al. 2013), mesoporous carbon (Niu et al. 2013) and liposomes 
containing bile salts (Chen et al. 2009). The micronized fenofibrate formulation (Lipanthyl® 
capsules) available in the market possesses a significant improvement in dissolution. behavior 
followed by increasing oral bioavailability. 
 
1.3 Liposome formulation 
After an API molecule is identified, it must be delivered to the target area of the body to have a 
pharmacological effect. Many new drug candidates possess poor water solubility and, therefore, low 
bioavailability after oral administration. In addition, non-specific. distribution of drug molecules to 
another site of the body results in undesirable side effects, and should be avoided as much as 
possible. These are challenging issues for formulation scientists to overcome. To achieve an ideal 
effect for an API, one of the common choices is nano-technological drug delivery system. There are 
a wide variety of drug carrier forms branching into nano-technological drug delivery systems, 
including liposomes, nanoparticles, polymeric micelles, and dendrimers. Liposome formulation is a 
valuable tool which connects drug discovery and (pre)clinical application (Banerjee 2001) and this 
research is focused on liposome as a drug delivery system.  
The word liposome comes from two Greek words: “Lipos” means fat and “Soma” means body. 
Liposome was first described in the mid-60s as a model of cellular membranes by a British 
hematologist named Alec Bangham at the Babraham Institute in Cambridge. Bangham and his 
colleague were testing the institute's new electron microscope when they made a noted observation 
about phospholipids forming closed multilamellar vesicle in an aqueous solution (Bangham et al. 
1965). Since this discovery, the field of liposome research has progressed enormously, and the 
applications area expanded from drug and gene delivery to cosmetics, diagnostics or food and 
chemical industry (Vishvakrama & Sharma 2014).  
A liposome is defined as a tiny phospholipid nanovesicles consisting of one or more concentric 
membranous lipid bilayers with central isolated aqueous spaces. Membranes are normally made of 
phospholipids with a hydrophilic head group and a lipophilic tail group consisted of long 
hydrocarbon chains. In an aqueous environment, the hydrophilic head has affinity towards water 
while, the hydrophobic tail is derived back by water to form a closed structure. Liposomes are the 
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drug carrier and are able to be loaded with a different variety of molecules, for instance, small drug 
molecules, proteins, nucleotides, and even plasmids. Nowadays, liposomal formulations of various 
therapeutic drugs are available in the market (Dua et al. 2012). 
The liposome can be formulated and processed to differ in size, composition, charge, and 
lamellarity. The type of bilayer components determines the “fluidity” and the charge of the lipid 
bilayer. For example, unsaturated phosphatidylcholine species extracted from natural sources (such 
as egg phosphatidylcholine) help bilayers to be more permeable and less stable, although the 
saturated phospholipids with long acyl chains (such as dipalmitoylphosphatidylcholine) form a 
rigid, impermeable bilayer structure (Akbarzadeh et al. 2013). Phospholipids spontaneously create 
closed structure when they are exposed to aqueous solutions. More importantly, the unique ability 
of liposomal systems to entrap both hydrophilic and lipophilic compounds enable a diverse range of 
drugs to be encapsulated by these vesicles. Hydrophilic molecules are encapsulated in the interior 
aqueous compartments; whereas lipophilic drugs can be accommodated in the lipid phase (Laouini 
et al. 2012). The surface of liposomes can be modified by the incorporation and covalent linkage of 
glycoproteins or synthetic polymers (Banerjee 2001). Figure 2 schematically illustrate the structure 
of liposome and lipophilic and hydrophilic drug entrapment models. Liposomes are used as drug 
delivery systems due to their excellent characteristics such as flexibility, biocompatibility, 
biodegradability, increasing therapeutic index of drug and efficacy, increasing the stability of 
entrapped drug from the hospital environment, reducing side effects, providing sustained release 
and acting as a reservoir of drug (Kavrakovski et al. 2013). 
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Figure 2. Liposome structure and lipophilic and hydrophilic entrapment positions (Laouini et al. 2012).  
 
1.4 Light Scattering 
The size of liposomes is normally determined by two methods; the electron microscopic 
examination, and dynamic light scattering (DLS) which sometimes referred as photon correlation 
spectroscopy (PCS) or quasi-elastic light scattering (QELS). Although electron microscopy is one 
of the most precise determination methods, it is very time-consuming and requires expensive 
equipment that may not be immediately in hand. In contrast, DLS is simple, automatized, and 
rapid and easy to perform. Light scattering is a consequence of random changes of the light after 
scattering from a solution or suspension. DLS is a non-invasive technique, which is most 
commonly used to measure the size of particles and molecules in suspension (Brittain 2003). 
DLS measures the ‘Brownian motion’ of particles, which is a random movement of microscopic 
particles suspended in the liquid due to collisions moving with molecules of the surrounding 
medium. It also records and analyses the intensity of absolute light scattering, which is 
represented as count rate in the unit of kilo counts per second (kcps).   
The light scattering properties of particles depend on the particle size and number. The 
correlation between scattering intensity and particle number is linear in diluted samples, which 
  
 
8 
means each particle scatters light independently without being influenced by proximate particles 
(Hulst & van de Hulst 1957; Elsayed & Cevc 2011). 
Shining a monochromatic light beam onto a suspension with random thermal moving molecules 
causes a Doppler Shift, which changes the wavelength of the light source. At that point, it is 
possible to calculate the size distribution and give a description of the particles motion (Brownian 
motion) in the suspension. The particle size is described as hydrodynamic radius and is modeled 
by the Stokes-Einstein relationship (Torchilin & Weissig 2003). The hydrodynamic radius is 
known as the diameter of a particle which has the same translational diffusion coefficient (symbol 
D). The Stokes-Einstein equation is described below: 
𝐷ℎ =
𝑘𝐵T
3𝜋𝜂𝐷𝑡
       𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1 
Where: 
Dh = hydrodynamic dimeter (the particle size)  
Dt = the translational diffusion coefficient (m2·s-1)  
kB = Boltzmann’s constant  
T = thermodynamic temperature (K) 
ŋ = viscosity of suspending liquid (N·s·m-2) 
 
The Stokes-Einstein equation connects diffusion coefficient measured by dynamic light scattering 
to the particle size. Although the calculations are completely handled by instrument software, it is 
noticeable that the equation reminds a few important points as follows. It is necessary to keep a 
constant temperature during the measurement, as the viscosity is strongly temperature-dependent. 
The translational diffusion coefficient is reliant on the type of ions in medium, the size of particle 
core on the surface and also the concentration of the testing suspension (Meyers n.d.; Clark et al. 
1970). The PCS instrument normally consists of six main components (Figure 3). Laser (1) 
provides the light source for illuminating the dynamic sample particles inside a cell (2). The 
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scattered light is measured by the detector (3), which is positioned at 173° or 90° (according to a 
different kind of instrument). The intensity of scattered light must be within a certain range; 
otherwise, the detector is not able to measure it correctly. The intensity of the laser source and the 
intensity of scattering are regulated by an attenuator (4). The scattering intensity signal is then 
passed to a correlator(5), which compares the scattering intensity at successive time intervals to 
derive it the rate at which intensity is varying. Data from correlator are sent to the computer (6). 
Special software analyses these data and calculates the size of particles in the sample 
(Instruments 2009). Finally, it should be noted that the particle size determined by dynamic light 
scattering is the hydrodynamic size that means, the determined particle size is the size of a sphere 
that diffuses the way as your particle. In this study, Zetasizer Nano ZS was used. 
 
 
Figure 3. The photon correlation spectroscopy instrument and its six main components (Instruments 2012). 
 
1.5 Dissolution 
The official pharmacopoeial dissolution methods are the simplest methods, which have been used 
to estimate the oral API behavior, the rate of absorption and the bioavailability. By far, the 
dissolution tests are used to evaluate the release of desire drug from both solid and semisolid 
dosage forms for quality control (QC) and product development purposes. In case of QC, 
dissolution methods are used to control deviation of manufacturing, control the consistency of 
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products from batch to batch and ensure continuing performance and product quality. With 
respect to research and development purposes, the tests are widely used to guide the new DDS 
development by predicting the behavior and release of drug in gastrointestinal conditions 
(Services & Administration 1997). 
In the dissolution process the drug molecules are transferred from a solid phase into an aqueous 
solution phase. In case of oral dosage forms the in vitro dissolution studies as the quality control 
testing are particularly important as they help the drug development scientists to estimate the 
function and effectiveness of the drug products after administrating them in patients (Sinko & AN 
2005). Furthermore, in vitro dissolution testing could equivalence the in vivo animal studies. The 
Food and Drug Administration (FDA) describes the testing condition for BCS I drugs which in 
vitro dissolution testing can completely simulates the in vivo studies (Guidance 1997). 
 
1.5.1 In vitro dissolution testing 
Various dissolution apparatus has been described across several Pharmacopoeias including 
United States Pharmacopeia (USP) and European Pharmacopeia (Ph.Eur.) for dissolution testing 
of drug substances and pharmaceutical dosage forms. To predict in vivo drug release, in vitro 
dissolution tests should reassemble the in vivo conditions that the DDS will encounter while 
passing through the human GI tract. Figure 4 shows the four most popular dissolution apparatus 
for oral dosage forms; the basket (apparatus I), the paddle (apparatus II), the reciprocating 
cylinder (apparatus III) and the flow-through cell (apparatus IV).  
The basket (USP I) and paddle (USP II) methods are by far used widely and are the chosen 
method for testing immediate release of oral solid dosage forms, as they are simple, easy to 
handle, well standardized and used world widely. In terms of flexibility, these methods can be 
used for evaluating the dissolution profile of a large variety of drugs and drug products, therefore, 
they are generally recommended by USP. The apparatus model consists. of a rotating basket or 
paddle in a large volume vessel filled. with 500 − 1000 mL of dissolution medium, but the typical 
volume is 900 mL (The United States Pharmacopeia and National Formulary 2014a; The 
European Directorate for the Quality of Medicines & Healthcare 2014). The dissolution media 
and the volumes are chosen to ensure sink conditions, enabling the release of entire dosage from 
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the formulation. Usually, samples are withdrawn and the undissolved materials are filtered off to 
spectroscopically quantify the dissolved fraction of the dose. 
 
 
Figure 4. The four popular apparatus models; (A) the basket (apparatus I), (B) the paddle (apparatus II),(C) 
the reciprocating cylinder (apparatus III), and (D) the flow-through cell (apparatus IV) (Kostewicz et al. 
2014). 
 
The principle of the reciprocating cylinder (USP III) is similar to disintegration tester, with the 
dosage form retained in a cylinder. The cylinder can be moved between a series consist of 
different media, this could be an advantage over the apparatus I and II by offering the possibility 
of achieving a dissolution profile which covers the entire GI transit. 
The flow-through cell (USP IV) evaluates formulation effects such as particle size and choice of 
excipients. The model is suitable to resemble both gastric and the intestinal fluids as they are easy 
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to vary the dissolution media compositions and the volume (small volume for small intestinal and 
larger volumes for sink conditions). The reciprocating cylinder (USP III) and the flow-through 
cell (USP IV) are alternative. models. They can be operated as open or closed. systems and are 
mostly used as modified-release. systems (Sinko & AN 2005). Figure 4 summarizes the operation 
steps of the compendial/conventional dissolutions methods. During the past decades, dissolution 
systems increasingly used biorelevant media made of aqueous salt solutions or buffers with or 
without the addition of surfactants, more importantly containing bile salts and phospholipids. 
Fasted State-Simulated Intestinal Fluid (FaSSIF) was the first biorelevant media suggested by 
Dressman and co-workers in 1998 (Galia et al. 1998). Since then, a lot of studies have been 
conducted to characterize the GI luminal fluid, with the consequence of developing various media 
simulating luminal conditions in different parts of GI tract. Nowadays, biorelevant dissolution 
media like FaSSIF or fasted state-simulated gastric fluid (FaSSGF) are frequently used by 
research groups worldwide as well as development groups in pharmaceutical industries (Kleberg 
et al. 2010).  
 
1.5.2 Theories of dissolution 
The dissolution procedure contains two individual steps; interfacial and transport. The primary 
step is the interfacial reaction, which helps the drug molecule to release from the solid surface in 
to solid-liquid interface. In the second step the molecules are transport from the solid-liquid 
phase into the available solution (Lee et al. 2008). 
The diffusion layer model is based on the Fick´s first law and states that the dissolution process 
is mostly controlled by diffusion of free molecules from the diffusion layer (liquid film layer 
surrounding the particle) into solution. The dissolution model was first developed by Noyes and 
Whitney and was finally modified by Nernst and Brunner (Noyes & Whitney 1897; Nernst 
1904). This model is controlled by the affinity of the drug molecules towards the solvent and 
described below. 
𝒅𝑴
𝒅𝒕
=  
𝑫𝑨
𝒉
 (𝑪𝒔 − 𝑪𝒕)              𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏 
 
Where M is the mass of solute dissolved in time t, dM/dt is the dissolution rate, A is the 
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effective surface area of the drug particles exposed to the solution, D is the diffusion coefficient 
of the drug, h is the thickness of the diffusion layer around each drug particle, Cs is the 
saturation solubility of the drug in the dissolution medium and Ct is the concentration of the 
drug at a time t in the bulk solution. According to this model, the effective surface area (A) and 
the boundary layer thickness (h) is held constant during dissolution. Moreover, the mentioned 
factors, the physicochemical properties of the drugs are also affected by the conditions in the 
gastrointestinal tract, for instance, phospholipids and bile salt concentrations bile, volume and 
hydrodynamics of the contents in the gastrointestinal tract (Dressman et al. 1998). Thus, for 
having a better prediction of the in vivo conditions, it is substantial to consider these mentioned 
parameters accordingly.  
1.6 Lipid digestion, drug solubilisation, and absorption 
Digestion and absorption of dietary lipids, as well as lipid-based formulations, occur throughout 
the gastrointestinal tract (GIT). The BCS class II drugs are poor oral absorption compounds and 
generally have a slow drug dissolution within the GIT (MacGregor et al. 1997; Dressman & Reppas 
2000). It has been proven that the absorption of these groups of molecules could be improved after 
formulating in a lipid-based construction (MacGregor et al. 1997; Birru et al. 2017). Following 
ingestion, Lipid digestion starts from the activity of lingual lipase, a lipolytic. enzyme secreted from 
the lingual serous. glands on the surface of the tongue (Cuiné et al. 2007; Tran, Siqueira, 
Amenitsch, Müllertz, et al. 2017). In the stomach, the gastric lipase as well as mechanical mixing 
transfer the dispersion of the lipids into an emulsion (Porter et al. 2007) and afterwards, the 
emulsified lipids in the stomach enter the small intestinal. The gastric emptying time could be 
different according to the size of the droplets, where the long chain fatty acids (FAs) strongly delay 
this timing (Armand et al. 1996).  
The gastric lipases, subclasses. of esterase, are responsible. for hydrolysis of lipids by breaking. 
the ester bond between the glycerol backbone and FAs (Cuine et al. 2008), and the chief cells in the 
fundic mucosa of the stomach are responsible for producing these type of enzymes (Porter et al. 
2007; Moreau et al. 1988). Human gastric lipase is generally active in a pH range of 2-7 and the 
optimal pH range between 4.5 and 5.5 (Larsen et al. 2011), whereas the pH-dependent pancreatic 
lipase shows the optimal activity between pH 6.5 and 8.0 (Armand et al. 1992). In humans, the lipid 
digestion in the stomach is responsible for about 10-30% of the hydrolysis of dietary fat while the 
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majority (more than 98%) of the hydrolysis of lipids occurs in the intestine with the help of 
pancreatic lipase (Cuiné et al. 2007).  
After entering the small intestine, pancreatic lipase helps the dispersion to get hydrolysed and 
absorbed (Embleton & Pouton 1997). The enterocytes in the intestine are the main site of GIT for 
absorption and consist of a glycerol backbone and three FAs chains linked by ester bonds. 
Pancreatic triacylglyceride lipase hydrolyses triacylglycerides at 1 and 3 positions and produces 2-
monoglyceride and two FAs from a triacylglyceride molecule it hydrolyses (Figure 5). 
 
 
 
   
Figure 5. Hydrolysis of triacylglycerols by pancreatic lipase (Vijayalakshmi et al. 2008). 
 
The natural existence of lipids in the intestine as well as the digested lipids stimulates secretion 
of bile from the gall bladder. The bile mixture consisted of bile salts, phospholipids, and cholesterol 
(Carey & Small 1978). The bile salt with a polar and nonpolar face has surfactant properties and 
emulsifies the existing lipids into a micelle form and resulted in solubilizing the lipophilic drug in 
the aqueous phase of intestinal fluid. The bile mixture together with the products of lipid digestion 
form colloidal structures. These colloidal structures facilitate the drug solubilisation by removing 
adsorbed water-soluble proteins including lipase from the surface and help to remove the restraining 
force for further digestion. The colloidal structures also facilitate the absorption by acting as a 
transportation vehicle in the lumen of intestine (Holm et al. 2013; Tran, Siqueira, Amenitsch, 
Rades, et al. 2017; Hernell et al. 1990). Figure 6 shows an overview of the lipid digestion process 
and the fate of the lipid-based drugs.  
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Figure 6. lipid digestion and drug solubilisation of a lipid-based formulation after oral administration 
(Müllertz et al. 2016). 
 
It has proven that fatty acids with more 12 carbon atoms are absorbed into the lymphatic 
circulation while fatty acids with chain length lower than 12 are primarily absorbed into the portal 
blood (Porter et al. 2007; Kiyasu et al. 1952). Molecules with log P higher than 5 and a lipid 
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solubility of a minimum of 50 mg/mL are expected to transport to lymphatic system (Porter & 
Charman 1997). The GI tract is very rich in terms of blood and lymphatic vessels, which makes the 
absorption of lipid digestion products and drug possible. However, the preferred absorption is in the 
blood as blood flow is significantly higher (500 times) than lymph flow (Reymond & Sucker 1988). 
1.7 Physiology of gastrointestinal tract of humans and rats  
Although the drug products produced for human-being purposes should be ideally tested in 
humans, which is quite impossible for the early screening stages of drug discovery, such as toxicity 
studies and drug efficacy. The rats are widely used in early drug development as they are low cost, 
small, easy to handle, reproducible, and most importantly have a very similar metabolism to 
humans (Do et al. 2011). Apart from similarities, there are important physiological differences 
between rats and the human body, which should be noted during developing in vitro lipolysis 
models (DeSesso & Jacobson 2001). The pH in the stomach of rats is within range of 3.5 to 4 while 
in humans it is from 1.5 to 3 (Kalantzi et al. 2006). In rats, the source of lipolytic activity in the 
stomach is from the lingual lipase (Hamosh & Scow 1973) while in humans, the lipase is from the 
gastric mucosa (Bernbäck et al. 1989). Moreover, the lipase activity in humans is more than rats 
(Anby et al. 2014). The concentrations of bile salts in humans is from 2-5 mM in the fasted state 
(Pedersen et al. 2000; Persson et al. 2005) and from 8-15 mM in the fed state (Hernell et al. 1990; 
Persson et al. 2005), while Tanaka et al. (2012) describe the rats bile concentration around 50 mM 
in the fasted state (Tanaka et al. 2012) and some other studies showing a range between 12 and 20 
mM, which are still higher than humans (Hagio et al. 2009; Vonk et al. 1978).  
Figure 7 illustrates the gastrointestinal tract (GIT) of human and rats. The rats have the same 
overall GIT organization as humans but there are a few important differences. The length of the 
human intestinal tract is just 5.5 times the length of the rat intestinal tract, in spite of the much 
larger body size of the human (70kg) compared with the rat (0.25kg). The relative length of the 
small intestine differs from the human that the jejunum makes up nearly the entire small intestine. 
The cecum of the rat is very large and does not have a vermiform appendix (Amidon et al. 1995). 
Furthermore, it has been proven that the administration of high volumes of liquid in humans 
increases the rate of gastric emptying (Sunesen et al. 2005), while in case of rats, this effect is still 
unclear (Gärtner 2002; Borowitz et al. 1971).  
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Nevertheless, it is generally assumed that the data from rat studies can be considered for humans 
(Lin 1995), however, the physiological differences should be taken into account, especially in case 
of comparing the results from the rat's studies to in vitro models simulating human conditions.  
 
 
Figure 7. Overview of the Gastrointestinal tract in a Human (A) and in Rat (B) (Amidon et al. 1995). 
 
1.8 In vitro lipolysis model and its parameters  
The gastrointestinal tract of a human being is a complicated organ involves enzymes, bile 
secretion, salts, pH, temperature, and agitation and although a lot of studies were carried out to 
simulate the in vivo condition of human GIT, still there is no unique in vitro model to evaluate the 
fate of different APIs. The in vitro assessment of lipid-based formulations should be different from 
the other solid dosage forms. In this case, since the lipid-based formulations incorporate lipids, 
there is always the possibility of formation micelles and moreover due to hydrolysis of the ester 
bonds of lipids by lipase enzyme available in GIT, monoglycerides and fatty acids will be released. 
Thus, the available lipid in LBF will affect the physiochemical processes occurring in the 
gastrointestinal tract (Cuine et al. 2008; Cuiné et al. 2007).  
The dynamic in vitro lipolysis model was first proposed by Zangenberg et al. in 2001 to provide 
an understanding of the rate and extent of lipolysis by simulating intestinal lipid digestion of 
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LbDDS (Zangenberg et al. 2001a; Zangenberg et al. 2001b). Furthermore, it gives the opportunity 
to determine the drug release by determining the drug content of solubilized or precipitated part 
during the lipid digestion (Dahan & Hoffman 2008; Vithani et al. 2017). 
An in vitro lipolysis model simulates the in vivo conditions of human GIT by using biorelevant 
dissolution media (Dressman & Reppas 2000). This in vitro model helps LbDDS to assess lipid 
digestion, the drug release as well as in vitro–in vivo correlations of water-soluble drugs (Dahan & 
Hoffman 2008). The human in vitro lipolysis model simulates the human GIT conditions and this 
may cause some troubles to correlate the in vivo results from the rat’s experiments. Siqueira and 
coworkers simulated an in vitro lipolysis model to predict the in vivo performance of the fasted state 
in rats (Siqueira et al. 2017). The lipid digestion was followed in this model by conditioning the rat 
gastric and intestinal tract. In this particular model, the gastric compartment is connected to 
intestinal part by a peristaltic pump. Moreover, according to the physiology of rats, some 
adjustments occurred in case of concentrations of bile salt and phospholipid, enzyme activity and 
importantly pH (Christensen et al. 2004). The main objective of an in vitro lipolysis model is to 
minimize the animal experiments due to ethical purposes. This will be possible by offering an 
inexpensive and fast way to predict the performance of a drug load lipid formulation in animals. 
The in vitro lipolysis model based on rat physiology consisted of the gastric compartment with 
pH 4 and intestinal part. The pH value is compromised between the pKa of the free fatty acids, pH 
range in the stomach and small intestinal especially the pH of duodenum (5 – 5.5) the main site of  
bile and pancreas enzyme secretion (Rune & Viskum 1969) , and the optimum pH for the 
pancreatin activity (Müllertz et al. 2010; Williams et al. 2012). In vitro lipolysis models is a pH-
controlled model which uses a biorelevant medium containing lipase, bile salts and phospholipids 
are used to simulate the lipolysis conditions in the stomach and small intestine (Crum et al. 2017; 
Kuentz 2012). Each compartment (gastric and intestinal) consisted of two titration devices (Ca2+ 
and NaOH), a thermostated double-wall reaction vessel, either magnetic or paddle stirrer to produce 
agitation, a pH electrode and a computer with software for evaluating titration and pH. A peristaltic 
pump transfers the gastric content into the intestinal compartment. Figure 8 schematically illustrates 
the compartments of the dynamic in vitro lipolysis. The rate of lipid digestion was controlled by 
addition of calcium ion into the lipolysis system. Titration of calcium could be either a fix addition 
at the beginning of the experiment or in a continuous manner during the experiment (Siqueira et al. 
2017). 
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As the lipolysis process goes on, the concentration of free fatty acids increase and this could 
affect the rate of lipolysis by inhibiting the pancreatic lipase due to the by binding to free lipids 
interface (Alvarez & Stella 1989; Borel et al. 1994). Nevertheless, at the opposite point bile salts 
and especially calcium form insoluble calcium fatty acids soaps involving one divalent calcium ion 
(Ca+2) and two FAs which facilitates the fatty acids elimination from the triglycerides by removing 
the oil/water interface (Larsen et al. 2011). Therefore, calcium is referred to be a salient factor to 
control the speed of lipolysis process (Armand et al. 1992). 
 The lipid digestion process initiates by pancreatic lipase which porcine pancreatin is the most 
common enzyme source used as a replacement for human pancreatic lipase (Zangenberg et al. 
2001a). Pure bile salts or a mixture of crude porcine or bovine bile extract and phosphatidylcholine 
are used to represent and mimic the composition of human bile salts and phospholipids (Kuentz 
2012; Griffin et al. 2014). It should be mentioned that the condition of the GIT (fed or fasted state) 
and the type and amount of the dietary affects the concentration of bile salts and phospholipids 
(Kalantzi et al. 2006; Jantratid et al. 2008). In vivo studies reported a wide range of ratios between 
the phospholipids and bile salts from 1 to 38.9, but the commonly employed ratio is ranged from 2 
to 6. The most used ratio in in vitro lipolysis models is 1:4, which is also used in this study (Kleberg 
et al. 2010).  
 
The release of FAs during the lipolysis causes a noticeable decrease in pH which is effectively 
determined by a pH electrode embedded in the system (Kuentz 2012). To maintain the pH constant 
from the beginning of lipolysis, the in vitro model automatically titrate the free FA available in the 
experiment environment by addition of sodium hydroxide (NaOH) which provides an indirect 
indication of the kinetics of lipid digestion (Williams et al. 2012; MacGregor et al. 1997). 
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Figure 8. Schematic illustration of in vitro lipolysis model and its different components containing gastric 
and intestinal steps and a peristaltic pump which transfers the dispersion of samples and gastric medium to 
the intestinal compartment. 
 
1.9 The relation between in vivo and in vitro data  
During early drug development, it is very vital to find out the right concentration of a drug to 
have an effective function at the site of action (Do et al. 2011; Klein 2010). This needs knowledge 
of dissolution and absorption occurring in GIT. The food and drug administration (FDA) describes 
a predictive mathematical model which provides information about the relationship between in vitro 
and in vivo response. This relationship is called In vitro-in vivo correlation (IVIVC) and help 
scientists to predict dissolution and absorption accurately (U. S. F. and D. Administration 1997). 
Therefore, the numbers of in vivo studies (in a human or animal body) reduce and resulted 
shortening the drug development time (Emami 2006). It is very often to build the animal studies 
according to the outcome of in vitro tests (Do et al. 2011). In case of BCS class II drugs, due to low 
water solubility dissolution is a time-limiting step for absorption and consequently, IVIVC is a 
useful support (Dressman & Reppas 2000).  
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There are some in vitro digestion models available to facilitate drug development by providing a 
platform to predict the in vivo behavior (Reymond & Sucker 1988; Dahan & Hoffman 2006). In 
vitro studies are usually carried out to characterize the GIT parameters affecting the drug 
absorption. Although some in vitro models showed good correlations for in vivo and in vitro results, 
still there is no specific and unique model to cover IVIVC of a broad range of lipid-based 
formulations(Elgart et al. 2013; Kaukonen et al. 2004). This is because of the dynamic and 
complicated condition of human GIT, which reacts differently facing various in vivo conditions. 
Moreover, in many previous studies, the in vivo results of rat studies are compared to the in vitro 
models simulating the human bodies (Thomas et al. 2014; Tran, Siqueira, Amenitsch, Müllertz, et 
al. 2017; Larsen et al. 2011). Due to the physiological difference between the GIT of the rats and 
human, it is important to improve the IVIVC by building an in vitro lipolysis model which 
simulates the rat GIT. These physiological differences applied to the enzyme activity, the 
phospholipids and bile salts concentrations and the volume of the relevant media (Di Maio & 
Carrier 2011). 
FDA guidance for industry classifies IVIVC into 3 individual levels based on the ability of the 
correlation to reveal the plasma drug concentration-time profile; 1) Level A correlation; the highest 
level of correlation shows a linear relationship between in vitro dissolution and the in vivo 
pharmacokinetics. This correlation level assessed by deconvolution procedure which compares the 
fractions of drug absorbed in the in vivo study to the fraction of drug dissolved in the in vitro model. 
Deconvolution could act as a guideline to assess the in vivo release or absorption (Emami 2006). 2) 
Level B correlation does not uniquely replicate the exact in vivo plasma level curve, since different 
in vivo curves could produce same mean residence time values. This means that the average in vitro 
dissolution time is compared either to the mean residence time or to the mean in vivo dissolution 
time. 3) Level C correlation shows a single point relationship between dissolution factors (e.g., 
Cmax, Tmax) and does not give a complete overview of plasma concentration-time curve which is a 
critical factor for prediction of drug performance (U. S. F. and D. Administration 1997).  
However, there are some examples that a unique IVIVC level was not capable to cover the 
IVIVC results (Dahan & Hoffman 2008). In these cases, the best way to show the correlation and 
similarity of trends could be by illustrating in vitro dissolution curves and in vitro dissolution 
profiles. 
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2.1 Materials 
2.1.1 Model compounds 
 
This study uses fenofibrate (FF) as a well-known, poorly water-soluble model compound in BCS 
Class II (Granero et al. 2005). Compounds within a BCS class behave in a similar manner in 
terms of solubility. Hence, fenofibrate can be considered as a representative of BCS Class II 
drugs, which have very low aqueous solubility of less than 0.3 mg/L. Furthermore, fenofibrate 
has a log P value of 5.24, which also indicates that it is a lipophilic drug (Hu et al. 2011). 
Fenofibrate is a prodrug, as it is a synthetic phenoxy-isobutyric acid derivative which is 
hydrolysed in vivo to yield fenofibric acid (Figure 9). This lowers plasma lipid levels by 
inhibiting triglyceride synthesis (Sharpe et al. 2002). Fenofibrate has a distribution volume of 
about 60 L and shows approximately high level of plasma protein binding (> 95%) to albumin 
(Miller & Spence 1998). The physicochemical properties of fenofibrate are listed in Table 1.  
 
After oral administration, fenofibrate is rapidly converted to fenofibric acid through hydrolysis of 
its ester bond. Hydrolysis is catalysed by both tissue and plasma esterases and initiates with 
absorption. After an oral administration, only the fenofibrate’s active metabolite fenofibric acid 
could be identified in the blood (Keating and Croom 2007; Chapman 1987; Yun et al. 2006; Buch 
2010). The chemical structures of fenofibrate and its active metabolite fenofibric acid (FFA) are 
given in Figure 9. 
 
Fibric acid derivatives (fibrates) are used for different metabolic disorders and mostly as 
hypolipidemic agents and they have significant treatment effects against the 
hypercholesterolaemia, mixed dyslipidaemia, hypertriglyceridaemia and diabetic dyslipidaemia. 
Fenofibrate is the isopropyl ester prodrug of fenofibric acid (2-[4-(4-chloro-benzoyl) phenoxy]-2-
methylpropanoic acid) and modifies the lipid level by activating peroxisome proliferator-
activated receptor α receptor (Gavzan et al. 2018). 
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Figure 9. Molecular structures of fenofibrate (a) and its active metabolite fenofibric acid (b). 
 
After oral delivery of fenofibrate, dissolution in the GI fluid is a critical precondition to estimate 
the occurrence in the GIT. As fenofibrate has low-water solubility, the dissolution step is the rate-
limiting step for the further steps. Fenofibrate comparing to the other fibrate derivatives has the 
lowest bioavailability, therefore, one of the successfully suggested approaches to improving 
solubilisation in the GI is focusing on the type of the formulation which is designed to carry the 
desire API. It is reported from the previous studies that after administration of micronized 
fenofibrate to human being, due to the size reduction, high water solubility was observed (Miller 
& Spence 1998). Therefore, to increase the water solubility, dissolution rate and consequently 
bioavailability is critical to design and select an appropriate formulation approach is critical for 
BCS Class II drugs, and especially fenofibrate. 
 
Table 1. Physicochemical properties of poorly water-soluble drug fenofibrate. 
 Fenofibrate Fenofibric acid 
Molecular formula C20H21ClO4 C17H15ClO4 
Molecular weight [g/mol] 360.8 318.8 
Solubility in water [µg/ml] < 0.3 a 70 b 
log P 5.24 c 3.99 b 
pKa - 3.1 b 
Melting point Tm [
◦C] 80 − 81 c 179 − 183 b 
Density [g/cm3] 1.18 ± 0.06 c - 
 
logP: octanol-water partition coefficient. 
a   (Granero et al. 2005) 
b   (Linn et al. 2012) 
c (Karmarkar et al. 2009) retrieved from: http://www.worldofchemicals.com/chemicals/chemical-
properties/fenofibrate.html 
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2.1.2 Chemicals and reagents 
Egg‐phosphatidylcholine E80 (E‐PC), Soluthin S 90 (S 90) and soybean phospholipids (Lipoid S 
PC), 99% was purchased from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol was obtained 
from Sigma–Aldrich (St. Louis, MO, USA), Fenofibrate was from Smruthi Organics Ltd (Solapur, 
India), Dulbecco’s phosphate buffered saline (PBS) was obtained from Gibco Life Technologies 
(Carlsbad, California, USA). Lime Bone Gelatine was from Gelita AG (Eberbach, Germany). 
Triton 1% (pure Triton X‐100) was yield from Roth GmbH & Co. KG (Karlsruhe, Germany). 
Sodium chloride, ≥ 99.5%, calcium chloride dihydrate, 99.0-102.0%, were purchased from Merck 
(Damstadt, Germany). Maleic acid, ≥ 99%, 4-bromobenzeneboronic acid, ≥ 95, pancreatin from 
porcine pancreas ≥ 3·U.S.P and bovine bile extract were purchased from (Sigma Aldrich). Tris 
(hydroxymethyl) aminomethane, ≥99% was purchased from Ohio (ICN Biomedicals). Ethanol (Ph. 
Eur. Grade) and Soybean oil (S-3547). Methanol ≥99%, acetonitrile, ≥ 99.9% were purchased from 
(Sigma, Aldrich). All other chemicals were obtained in the highest purity from the usual 
commercial sources. 
 
2.2 Liposome Preparation 
In this study, liposomes were prepared by the conventional thin film hydration method (Bangham et 
al., 1965) to produce multilamellar vesicles (MLVs). Different type of phosphatidylcholins 
including egg phosphatidylcholins (EPC), soy bean phosphatidylcholins (SPC) and Soluthin S90, 
together with cholesterol and different concentrations of fenofibrate were separately dissolved in a 
mixture of chloroform and methanol in a ratio of 9 to 1 respectively to a final concentration of 100 
mM. To prepare different liposomal formulations (as listed in Table 2. List of liposome 
compositions.), specific quantities of dissolved materials were mixed according to the desired final 
concentrations. The mixture was transferred into a round-bottomed flask in a 40 °C water bath and 
the solvent was removed using a rotatory evaporator to leave a thin, smooth lipid film around the 
flask. The flask was kept under vacuum conditions for 1 hour to ensure that all solvent was 
removed from the mixture and that a fully dried lipid mixture had formed. The lipid film was then 
hydrated using phosphate buffered saline (PBS) or a solution of gelatine (Gel) dissolved in PBS at 
different concentrations. Finally, vesicular phospholipid gels (VPGs) were formed using either dual 
asymmetric centrifugation or a probe sonicator, as described in sections 2.2.1 and 2.2.2. 
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Table 2. List of liposome compositions.  
Samples Phosphatidylcholin 
concentration 
Cholesterol 
concentration 
Fenofibrate 
concentration 
Gelatine 
Concentration 
Blank_0%Gel 75 mg 25 mg 0 mg 0 μg in 1 mL PBS 
Blank_15%Gel 75 mg 25 mg 0 mg 150 μg in 1 mL PBS 
Blank_20%Gel 75 mg 25 mg 0 mg 200 μg in 1 mL PBS 
2.5FF_0%Gel 75 mg 22.5 mg 2.5 mg 0 μg in 1 mL PBS 
2.5FF_15%Gel 75 mg 22.5 mg 2.5 mg 150 μg in 1 mL PBS 
2.5FF_20%Gel 75 mg 22.5 mg 2.5 mg 200 μg in 1 mL PBS 
4FF_0%Gel 75 mg 21 mg 4 mg 0 μg in 1 mL PBS 
4FF_15%Gel 75 mg 21 mg 4 mg 150 μg in 1 mL PBS 
4FF_20%Gel 75 mg 21 mg 4 mg 200 μg in 1 mL PBS 
 
Table 2 provides information about the type and amount of each component of the formulations. 
For instance, to prepare 4FF_20% Gel formulations in PBS or 20% gelatine, a specific volume of 
chloroform/methanol-dissolved solution containing 4 mg of Fenofibrate, 21 mg of cholesterol and 
75 mg of the intended PC was transferred into the rotatory evaporator. Depending on the purpose of 
the study and the type of experiment, different concentrations of liposomes are required. In case of 
this example, in the rehydration step, an aqueous solution containing 200 μg of gelatine dispersed in 
1 mL PBS was added to the thin layer of lipid film. 
 
2.2.1 Dual asymmetric centrifugation  
Dual asymmetric centrifugation (DAC) was established in the 1970s as a rapid and useful 
technology for mixing viscous components using apparatus known as a speedmixer (Wang et al. 
2002). Massing and co-workers were the first to use a speedmixer to produce multilamellar 
liposomes (Massing et al. 2008). DAC is a specific centrifugation method which turns the vials 
around the main rotation axis at a specific angle and distinct speed and distance. While the vials are 
spinning around the centre of the centrifuge in the DAC process, they simultaneously rotate around 
their own individual centre (vertical axis) with the normal centrifugation process. These two 
overlying movements of the sample materials in the centrifugation vial result in shear forces that 
help the viscus materials to mix completely. The normal rotation of the centrifugation vial around 
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the main axis forces material outwards while the smaller rotation around the vertical centre 
constantly pushes the material in the opposite direction (see Figure 10 and Figure 11). 
 
Figure 10. Schematic illustration of dual asymmetric centrifuging (Huang et al. 2014). 
 
 
Figure 11.Dual asymmetric centrifuge (DAC) with open lid view (A) and the rotation chamber (B). (Massing 
et al. 2008). 
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In addition to mixing the viscous materials, the shear forces arising from the centrifugal movement 
can be used for other purposes. These constant, strong shear forces can facilitate homogenization of 
the material, and this process and method of preparation can therefore be proposed as a fast and 
effective method to produce viscous, uniquely sized liposomes. The maximum speed at which DAC 
can be used is 3540 rpm, which is the speed that was primarily used in this study (Massing et al. 
2008).  
To achieve a homogenized product using DAC, the lipid concentration should be within the range 
of 350–450 mg/ml. In this study, the dried lipid film mass was added to the aqueous solution (PBS 
with and without gelatine) at a ratio of 2:3, but for glass beads (ø 0.75–1 mm), a ratio of 2:5 was 
maintained. The addition of glass beads, or indeed any kind of bead (e.g. stainless beads), is highly 
recommended as it helps the mixture to form small, homogenized and highly reproducible 
liposomes. The mixture of lipid film, aqueous solution and glass beads was centrifuged and 
homogenized for 30 minutes at a maximum speed of 3540 rpm. Notably, some factors can affect the 
liposome size such as the lipid concentration, DAC speed, homogenization time and addition of 
glass beads. One advantage of this preparation method over other methods used to prepare 
liposomes is that, since the final product is highly viscous, it is possible to dilute the product to any 
desired final concentrations for different experiment purposes. 
 
2.2.2 Probe sonication 
Sonication (using either a bath or a probe tip sonicator) is used widely for the preparation of 
unilamellar and multilamellar liposomes (Maulucci et al. 2005). Probe tip sonicators transfer high 
energy to the lipid dispersion, which can result in overheating and subsequent degradation of the 
lipid suspension. Moreover, the sonicator tips can release titanium particles into the suspension. 
Due to these disadvantages, the best way to use the sonication to prepare liposomes is to combine 
the probe tip sonicator and the water bath methods. Using this approach, the sonicator tip is placed 
in a sample tube containing the dispersion, which is placed in the bath sonicator, and the sonication 
process is typically run for 5–10 minutes to produce a hazy and non-clear solution which scatters 
light. The size and dispersity of the solution can be affected by different factors including the type 
and concentration of the mixture, temperature, power, volume and duration of sonication. The 
liposomal formulation should not be stored for a long period of time as the liposomes are naturally 
unstable and could fuse spontaneously. 
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Depending on the desired final concentration, the mass of dried lipid film containing different 
concentrations of lipid and drug (Table 2) was dispersed into 10 mL of aqueous solution containing 
various concentrations of gelatine in PBS. The mixture was then applied to probe sonicator with an 
ultrasonic probe (50/60 KHz, 230V, Chemical Instruments AB, Sweden) at 80% ultrasonic power 
amplitude for 10 min to form the fenofibrate-loaded lipid vesicles. The probe, with a tip diameter of 
6 mm, was dipped about 15 mm in the liquid. The ultrasound burst was set to 3 s with a pause of 7 s 
between two ultrasound bursts. The sample vial was kept in a temperature-controlled water bath to 
prevent heat damage (4°C). 
 
2.3 Size and Size Distribution 
Size determinations including hydrodynamic size (Z average) and polydispersity index (PDI) were 
determined using methods based on dynamic light scattering, which measures the intensity of the 
scattered light produced on the movement of the existing particles in the sample. The light-
scattering method can be applied to particles with a diameter ranging from 0.3 nm to about 10 μm 
(Malvern Instruments Limited 2003). Of note, the desired method does not calculate the particle 
size directly; it measures the size indirectly according to the fluctuation effects detected by the 
scattering device. Therefore, it may give unreliable results for particles that are not spherical in 
shape (Müller et al. 2000). In this study, liposome dispersions were measured at 25 °C by photon 
correlation spectroscopy on a Malvern Zetasizer Nano® instrument (Malvern Instruments Ltd., 
Worcestershire, United Kingdom) and all measurements were repeated tree times. The Z average 
was used to determine the hydrodynamic size (diameter) of particles where PDI indicates the width 
of size distribution and the homogeneity of the particles in the system. Dispersions with a PDI of 
less than 0.2–0.3 can be considered as a homogenous system, where PDI 1 shows a heterogeneous 
dispersion (Schubert & Müller-Goymann 2005). 
 
2.4 Light-Scattering Measurements 
In this study, a Zetasizer instrument using software version 6.20 was used for purposes other 
than the determination of particle size. The instrument was also used to measure absolute light 
scattering intensities, which gives an arithmetic mean of count rate and is reported as mean 
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count rate in kilo counts per second (kcps). Liposome samples were diluted with water to 
concentrations of 20−200 µg/ml. At this range of concentration, stable particle size is ensured 
by increasing the solubility and preventing particle dissolution (Brittain 2003). The size 
measurements were conducted at position 4.65 mm, with automated attenuator settings at a 
temperature of 25 ◦C. The Zetasizer instrument was used with a He-Ne laser (wavelength 633 
nm, 4.0 mW) and a photodiode detector at a detection angle of 173◦. The incident laser light 
could be set from 0 (total laser block) to 11 (full laser power), but the ideal concentrations are 
reached when the attenuation factors are set from 7 to 9. In this study, all determinations were 
performed at attenuator settings between 7 and 9 for absolute light scattering measurements. The 
measurement position, which is the distance from the cuvette wall, was always at 4.65 mm to 
ensure a constant scattering volume. Since attenuator and position settings can influence the 
intensity of scattered light, they were both fixed and set to give scattering intensity values in the 
range of 100−2000 kcps. All measurements were performed in disposable semi-micro 
polystyrene cuvettes with lids at a temperature of 25 ◦C, and were repeated three times. 
 
2.5 Cryogenic Electron Microscopy  
Cryogenic electron microscopy (Cryo_EM) is a type of transmission electron microscopy (TEM) 
which uses samples at cryogenic temperatures (generally liquid nitrogen temperature) to study the 
structures of different biological molecules (Kühlbrandt 2014). Cryo_EM allows the observation of 
specimens which are not fixed or even stained, and therefore allows samples to be examined in their 
natural environment. This can be considered as one of the advantages of this biological method over 
other structural methods such as X-ray crystallography, in which specimens need to be crystalized 
and consequently can undergo irrelevant conformational changes (Callaway 2015). 
The working principle of TEM is the same as for normal light microscopy, except that the source of 
the light is small-wavelength electrons instead of the normal light. TEMs generally provide 
electrons from two different sources, including field emission guns and thermionic electron guns. 
To verify the structure of liposomes as well as determine the effect of gelatine on liposome 
integrity, cryo_transmission electron microscopy images were prepared. Liposome dispersions 
containing 4% (w/w) of fenofibrate, prepared in either PBS (as a control) or in a solution of gelatine 
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dissolved in PBS, were diluted in PBS to a concentration of 10 mg/mL and applied to a glow-
discharged Quantifoil sample support grid. The grids (2/2) were glow discharged for 10 s in a 
mixture of H2 and O2 gas and the dispersion was blotted from one side at 4 °C with 100% humidity 
for 8–10 s using a Vitrobot (FEI, Hillsboro, Oregon). Directly after blotting, the grid was dipped 
into liquid high heat-capacity ethane. To provide clear images, it is essential that the freezing 
process is as quick as possible to prevent ice formation around the specimens. The grids were 
viewed under a Titan Krios microscope (FEI, Hillsboro, Oregon) equipped with a Quantum 963 SE 
energy filter operated at 200 kV and liquid nitrogen (LN) temperature. Zero-loss filtered images 
were taken at 64,000× magnification (pixel size 2.2 A) using a 2k Ultrascan Quantum CCD camera. 
 
2.6 Drug Entrapment Efficiency 
The drug entrapment (encapsulation) efficiency, which corresponded to the amount of drug that 
could be incorporated in the liposomes, was determined by directly measuring the concentration of 
the loaded drug in the lipophilic layer of the liposomes. The free and unloaded drug in suspension 
was separated from the lipid vesicular particles using Sephadex G-50 chromatography. About 1.5 g 
Sephadex G-50 was packed into a 10-cm glass column with an inner diameter of 1 cm. After 
draining the gravity column with running buffer, a suspension of fenofibrate-loaded liposomes was 
applied and the free drug was separated from the drug-loaded liposomes according to size and 
gravity. The remaining eluent containing liposomes was treated with 1% Triton-X100 to disrupt the 
vesicular structure and release the loaded fenofibrate. The content of fenofibrate was determined 
using an Agilent 1100 HPLC system (UltiMate3000, Dionex, Dreieich, Germany). 
The entrapment efficiency (%EE) was calculated as: 
%EE = Wc/Wt × 100 
where Wc and Wt denote the drug content in liposomes and total drug in the dispersion, 
respectively. 
 
2.6.1 High-performance liquid chromatography  
Fenofibrate and fenofibric acid concentrations were determined by high-performance liquid 
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chromatography (HPLC). All samples were diluted in HPLC vials, as samples containing gelatine 
may interfere with HPLC performance by precipitating the determination column and blocking the 
running flow in the HPLC. For each sample, three independent dilutions were prepared and two 
injections were performed from each vial. To evaluate the accuracy of the system, a complete 
calibration of the method was repeated every 3 months, and for each sequence, new control 
standards were run. Calibration standards were prepared in extraction medium at concentrations of 
1−500 µg/ml. The chromatograms were analyzed using Chromeleon software. The HPLC 
parameters are given in Table 3. 
 
Table 3. An overview on high pressure liquid chromatography (HPLC) method parameters for quantification 
of fenofibrate. 
Mobile phase 
Eluent A 
Eluent B 
 
H2O/AcN: 95/5 + 0.01% TFA 
H2O/AcN: 5/95 + 0.01% TFA 
Extraction medium H2O/AcN: 20/80 
Column Zorbax Eclipse Plus C18 4.6 x 50mm 3.5µm 
Column temperature 30 ◦C 
Flow 2 ml/min 
Gradient 0 min A/B 100/0 
3 min A/B 80/20 
6.8 min A/B 30/70 
8.3 min A/B 0/100 
11 min A/B 0/100 
12 min A/B 100/0 
Injection volume 20 µl 
Sample temperature 20 ◦C 
Detection wavelength 288 nm 
in coefficients of determination R2 > 0.995. 
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2.7 X-Ray Powder Diffraction  
Recent studies have shown that, during in vitro lipolysis, amorphous precipitations have a faster 
dissolution rate than the crystalline phase (Xiao et al. 2016). The existence of crystals in the 
formulation facilitates precipitation and, therefore, fewer drugs become solubilized and absorbed. 
One effective method to distinguish between the presence of crystal (long-range order) and 
amorphous forms in the samples and to evaluate the crystal structure of the API incorporated in the 
liposomes is by the analysis of X-ray powder diffraction (XRPD) patterns obtained from X-rays 
scattered by the sample. The X-ray amorphous form is obtained from a solid powder that contains 
no crystalline or long-range order pattern. The XRPD patterns act as a unique fingerprint for 
crystalline substances and provide information about the length of the short and long spacing of the 
lipid structure of the liposomal formulation (Mehnert & Mäder 2012). The sets and positions of the 
picks can be compared with the crystallographic unit cells available in the database in order to 
identify the crystalline substances. To obtain perfect X-ray picks, it is important to obtain patterns 
with a high resolution and low background. 
There are some parameters which can affect the crystallization behaviour of the testing materials; 
molecular structure, type of the solvent, pressure, temperature, rate of crystallization, and presence 
of impurities. The lipids are typically known to be polymorphisms and they crystallize in different 
positions and arrangements: α, β' and β modification. (Sato 2001). These factors strongly affect the 
drug incorporation and release rates. 
X-ray powder diffractograms were measured at ambient conditions on a PANalytical X'Pert Pro 
diffractometer equipped with a PIXcel detector (PANalaytical B.V., Almelo, the Netherlands). 
Samples were placed on a stainless-steel disk for measurement, and a continuous 2θ scan was 
performed in the range of 2–40° using Cu Kα radiation (λ = 1.54187 Å). Kβ radiation was 
eliminated using a nickel filter. The applied voltage and current were 45 kV and 40 mA 
respectively. Each measurement was performed with a step size of 0.0260°2θ and a speed of 
0.0336°/s. To avoid the effect of preferred orientation, the samples were rotating during the 
experiment. Data were collected using X'Pert data collector version 2.2, and were analyzed using 
X'Pert high score plus version 2.2.4 (both from PANalaytical B.V.). 
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2.8 Dissolution Behaviour  
The early stage of oral absorption of a pharmaceutical API is the dissolution of drug in the 
physiological environment of the GI tract. Drug particles first need to be dissolved in the GI fluid to 
permeate the mucosa at the absorptive sites in the GI tract (1); therefore, the solubility of the drug 
and its dissolution rate are critical for determining the in vivo behaviour (Klein 2010). 
To evaluate the dissolution behaviour of solidified VPGs, a paddle dissolution apparatus with two 
kinds of dissolution media were used. The first model used the simulated intestinal fluid (SIF) to 
assess the release of liposomes from the semi-solid formulation, while the second model used two 
different biorelevant media containing fasted state simulated intestinal fluid (FaSSIF) and fasted 
state simulated gastric fluid (FaSSGF) to determine drug release from the desire formulation. The 
composition of used dissolution media is given in Table 4. 
 
Table 4. The chemical composition and properties of different tested intestinal fluids; simulated intestinal 
fluid (SIF) (Gray & Dressman 1996), fasted state simulated intestinal fluid (FaSSIF) and fasted state 
simulated gastric fluid (FaSSGF) (Klein 2010). 
 SIF FaSSIF FaSSGF 
Sodium taurocholate - 3 mM 80 µM 
Lecithin - 0.75 mM 20 µM 
Pepsin - - 0.1 g 
NaCl - 6.186 g 34.2 mM 
NaOH 0.896 g qs. pH 6.5 - 
NaH2PO4.H2O - 3.438 g - 
KH2PO4 6.805 g - - 
Deionized water qs. 1000 mL 1000 mL 1000 mL 
pH 6.8 6.5 1.6 
Osmolality (mOsmol/kg) 113 270 120.7 ± 2.5 
Surface tension (mN/m) Not available 54 42.6 
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2.8.1 Release of liposomes 
The initial dissolution tests were carried out by using USP Apparatus II to evaluate the release of 
liposomes from the semi-solid formulation. In each dissolution experiment, 900 mL of simulated 
intestinal fluid (pH 6.8) was used as a testing medium and all experiments were conducted at 37 ± 
0.5°C with a paddle rotation speed of 75 rpm over 2 h. Sampling aliquots of 1 ml were withdrawn 
at 5, 20, 40, 60, 80, 100 and 120 min, and were replaced with an equal volume of fresh medium 
maintained at the same temperature. Each dissolution test was performed in triplicate. Where 
liposome gel was not completely dissolved within 2 hours, an additional sample was taken at 150 
and 180 min. After sampling, the solutions were filtered through a 0.22 μm syringe filter and 
analyzed by PCS using a Zetasizer Nano ZS. The derived count rate, which gives the arithmetic 
mean of the scattering signal, was determined to show the number of particles converted from the 
semi-solid formulation into free liposomes. Therefore, the derived count rate was standardized to 
show the percent release of liposomes. To determine the liposome quality, the liposome size and 
size distribution were determined.  
 
2.8.2 Drug release in different biorelevant media 
The use of biorelevant media such as FaSSIF and FaSSGF has appeared in the past decade and has 
developed to be uses as a standard medium in pharmaceutical dissolution testing, particularly if in 
vitro–in vivo correlation is intended (Galia et al. 1998; Lee et al. 2008). The lipid-based 
formulations were evaluated for their stability in different biorelevant media: FaSSIF (pH 6.5) and 
FaSSGF (pH 1.6), prepared according to the USP. 
The dissolution experiments were conducted as described in Section 2.7.1 to determine the release 
of fenofibrate from the respective formulation. A volume of 900 mL of each biorelevant media was 
applied to the glass vessel of the USP II paddle apparatus at 37 ± 0.5 °C with a speed of 75 rpm, 
according to the FDA instructions. Samples were collected at 5, 10, 20, 45, 60, 90, 120 and 180 
min. For each sampling, 2 mL of the experimental solution was collected and replaced with fresh 
medium at the same temperature. After filtration through a 0.22 μm syringe filter, samples were 
divided into two separated stocks. The first stock was used to determine the release of fenofibrate 
from the liposomes. The released fenofibrate was separated from the liposomes using a Sephadex® 
G50 gel exclusion chromatographic column eluted with PBS (pH 7.4). The eluent containing 
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liposomes was treated with 1% Triton-X100 to disrupt the vesicular structure to release fenofibrate. 
The content of fenofibrate was determined by an Agilent 1100 HPLC system (UltiMate 3000, 
Dionex, Dreieich, Germany). The percent of drug release (% release) in different media at the given 
timepoint was calculated from the equation: 
EE% =
Wt − Wc
Wt
 × 100 
Where Wc is the drug content incorporated into liposomes at different time points and Wt is the total 
drug content in the dispersion. The second stock was used in parallel to evaluate the stability of 
liposomes in terms of particle size and also dispersity using a Zetasizer Nano ZS. 
 
2.9 Storage Stability 
In the development of an API, it is vital to evaluate the stability of the formulation under storage 
conditions. Testing should cover the physical and thermal stability, sensitivity to moisture and 
potential to lose solvent. Different environmental factors can affect the physical stability of 
liposomes by changing their size and distribution, integrity and saturation of fatty acid groups. 
During storage, liposomal vesicles are at risk of aggregation, fusion and leakage of the contained 
API, and the lipid component of liposomes and type of incorporated drug substance plays an 
important role in these processes (Administration 2015). 
Conventional and matrix liposomes were assessed for storage stability over a period of 3 months 
according to ICH guidelines, with minor changes (Jain et al. 2012). Briefly, samples containing 
fenofibrate with and without gelatine were stored at 4 °C or room temperature (25°C) at relative 
humidity ≤55%. The liposomal suspensions were observed each month for changes in physical 
appearance, such as the size and size distribution, as indicators of kinetic stability. 
2.10 In Vitro Lipolysis Model 
The intestinal in vitro lipolysis model developed by Zangenberg et al., with some modifications, 
was used to investigate the lipid digestion and solubilisation of the drug in the bio-relevant media. 
An in vitro lipolysis study simulating the lipid fate in the human GIT was performed as described 
below. All media and required solutions were prepared in advance. 
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2.10.1 Media and solution preparation 
For each experiment, the in vitro lipolysis model used freshly prepared solutions and bio-relevant 
media. The media and solutions were prepared as detailed as follows. 
 
a) Preparation of bio-relevant media 
To prepare the gastric and intestinal bio-relevant media, all excipients were weighed out separately 
and transferred into a 500 mL glass beaker to which 200 mL purified water was added. The solution 
was mixed with a spoon and transferred to a 500 mL volumetric flask. The solution was protected 
from light and stirred overnight with a magnetic stirring bar, and then the pH was adjusted to 6.5 for 
intestinal media and pH 4 for gastric media before the volume was adjusted to 500 mL with purified 
water. The prepared solution was used within the period of 24–48 hours. Table 5 shows the 
composition of the bio-relevant media used in the in vitro lipid digestion. 
Table 5. The composition of digestion media used in in vitro human lipolysis and in vitro rat lipolysis 
models 
 Human                              Rat 
 Intestinal medium Gastric medium Intestinal medium 
Total volume (mL) 30-40 50 100 
Bile bovine (mM) 2.95 0.08 15.00 1  
Phosphatidyl choline (mM) 0.26 0.02 1.65 2 
Sodium chloride (mM) 73.0 34.2 70.0 
Calcium chloride (mM) 1.4 - - 
Maleic acid 2.0 2.0 2.0 
Tris maleate (mM) 2.0 2.0 2.0 
pH 6.5 ± 0.1 4.0 ± 0.5 3 6.5 ± 0.1 3  
Lipase source Porcine pancreatin Rhizopus oryzae Porcine pancreatin 
Lipase activity  660 USP units/mL 12.0 TBU*/mL 4 800 USP*/mL 5  
* TBU: tributyrin unit; USP: United States pharmacopeia. 
1 (Hagio et al. 2009) 
2 (Holm et al. 2013) 
3 (Kararli 1995) 
4 (Sassene et al. 2016) 
5 (Mosgaard et al. 2017) 
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b) Preparation of pancreatic and gastric lipase solution 
The precise mechanism of rat pancreatin activity remains unclear by now (Anby et al. 2014; 
Tønsberg et al. 2011), although current in vitro lipolysis models simulating the human 
conditions primarily use pancreatin enzymes with activity between 500–800 USP/mL 
(Mosgaard et al. 2017; Larsen et al. 2013). The enzyme activity used in this model was 800 
USP/mL, as used by (Christophersen et al. 2014). Lipolysis is initiated. by the addition of a 
certain amount of pancreatic lipase solution and, after sample collection; lipid digestion is 
inhibited by the addition of 4-bromobenzeneboronic acid (4-BBBA) solution at a concentration 
of 1 M. 
Pancreatic and gastric lipase solutions were prepared immediately prior to use to prevent loss of 
activity. Briefly, 78.65 mg of the pancreatin was suspended in 5 mL water to obtain an activity of 
800 USP/mL. In previous experiments, pancreatin was added to the intestinal medium, but to avoid 
initiating the digestion of lipids existing in the medium, the enzymatic solution was added to water. 
The suspensions were centrifuged for 7 min at 4000 rpm at 4°C in a Heraeus Megafuge 16R 
centrifuge (Langensenbold, Germany) and 4 mL of the resulting supernatant was added to the lipid 
digestion vessel to initiate the digestion process. For gastric enzymes, 8.33 mL of Rhyzopus enzyme 
was added to 3 mL of gastric medium. 
 
c) Preparation of calcium chloride and sodium hydroxide solutions 
A solution of calcium chloride and sodium hydroxide were prepared according to Table 6. The 
mixtures were prepared from the desire chemical resources and after dissolving in Milli-Q water, 
they stirred overnight at room temperature to produce clear and homogenous solutions. 
Table 6. Chemical properties of calcium chloride and sodium hydroxide solutions 
 
Concentration 
(M) 
Final volume 
(L) 
Chemical resource 
NaOH 0.5 1 CaCl2•2H2O 
CaCl2 0.5 1 NaOH pellets 
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2.10.2  Liposome samples 
The liposomal formulations were prepared using the probe sonication method from various 
phosphatidylcholine compositions, namely E-PC, S-PC or Soluthin S 90, both with and without 
gelatine as listed in Table 7. For this specific experiment, liposomes were prepared at a 
concentration of 0.625% (0.625 g/100 mL) and subsequently monitored for size and polydispersity 
with the help of a Zetasizer Nano ZS. In each lipolysis run, 2 mL of samples containing 125 mg of 
the formulation (5 mg FF + 45 mg cholesterol + 75 mg of the desired lipid) was used.  
Table 7. The chemical properties of the liposome samples tested in in vitro lipolysis. 
Samples PC type Fenofibrate 
W/W (%) 
Gelatine concentration 
in PBS 
Concentration 
W/V (%) 
4%FF_0%Gel_EPC EPC 4% 0 μg in 1 mL PBS 0.625% 
4%FF_20%Gel_EPC EPC 4% 20 μg in 1 mL PBS 0.625% 
4%FF_0%Gel_SPC SPC 4% 0 μg in 1 mL PBS 0.625% 
4%FF_20%Gel_SPC SPC 4% 20 μg in 1 mL PBS 0.625% 
4%FF_0%Gel_S 90 Soluthin S 90 4% 0 μg in 1 mL PBS 0.625% 
4%FF_20%Gel_S 90 Soluthin S 90 4% 20 μg in 1 mL PBS 0.625% 
 
2.10.3 Dynamic in vitro lipolysis assay 
The in vitro study was performed using 5 mL of gastric medium (pH 4) and 20 mL of intestinal 
medium (pH 6.5) added to the gastric and intestinal compartments, respectively. The pH was set at 
6.5 by potentiometric titration. using 809 Titrando titrators combined with an Ecotrode. Plus pH 
electrode. There were two Dosino dosing units which were connected; one was filled. with 0.5 M 
sodium hydroxide (NaOH) and the second was filled with 0.5 M calcium chloride (CaCl2). The 
flow rate for the CaCl2unit was set to 0.01 mL/min. A stirrer with a propeller. was immersed. in the 
bio-relevant media located in a thermostatic glass vessel (KGW-Isotherm, Karlsruhe, Germany). 
The titrator. was connected to a computer and controlled by Tiamo software versions 1.1 and 2.0. 
The whole lipolysis system (except the glass vessel) was obtained from Metrohm AG (Herisau, 
Switzerland). The temperature. in the glass vessel was kept constant. at 37±1°C using a Julabo 
water bath (Buch & Holm, Herlev, Denmark). The lipolysis apparatus is illustrated in Figure 12. 
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Figure 12. The experimental in vitro lipolysis compartment. 
 
The experiment workup started when 2 mL of samples containing 125 mg of liposomes suspended 
in PBS was added to 2 mL of gastric medium, and 3 mL of gastric lipase enzyme was then added to 
the gastric medium in the thermostated vessel (gastric vessel) with stirring. The pH of the gastric 
medium was monitored and manually adjusted by adding a few drops of 0.05 M HCL after the 
addition of samples. The next step was to prepare the pump for transferring the gastric suspension 
into the intestinal compartment, which was the main environment for lipolysis testing. 
The system was activated after adding 5 mL of pancreatin lipase solution to 20 mL of intestinal 
medium while simultaneously turning on the transfer pump. The pump transferred a specific 
volume from the gastric to the intestinal compartment at a flow rate of 0.5 mL/min. A computer-
controlled pump automatically added CaCl2 at a constant rate of 0.01 mL/min into the intestinal 
compartment. The pH of the intestinal compartment was set at 6.5 by titrating the required amount 
of NaOH. The gastric vessel was empty after 20 minutes. The continuous steps of the rat in vitro 
lipolysis model are shown schematically in Figure 13. 
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Figure 13. Schematic illustration of dynamic in vitro lipolysis model over the time. 
 
Samples were taken at 5, 15, 30 and 60 min, at different volumes (100 μL and 1 mL) 
simultaneously. Each time a sample was taken, the sample volume was replaced with fresh 
intestinal medium. The 100 μL sample was quickly diluted with 900 μL of methanol and 
centrifuged in an Eppendorf Centrifuge 5417R (Germany) at 16,000 rpm for 20 min at 37°C, and 
the resulting supernatant was collected for HPLC analysis. These samples contained total 
fenofibrate concentrations (T-samples). The 1 mL sample was used to determine the concentration 
of fenofibrate in the different phases. Briefly, 7 μl of 1.0 M 4-BPBA (4-Bromo-phenylboronic acid) 
solution was added to the 1 ml sample to inhibit lipase activity. The mixture was centrifuged in 
Eppendorf Centrifuge 5417R (Germany) at the speed of 13.3 rpm for 15 min at 37 °C and the 
aqueous (supernatant) and pellet phases were separated. The supernatant phase was termed the 
aqueous phase and the precipitate was the pellet phase. Next, 200 μl of supernatant from the middle 
of the aqueous phase was diluted with 800 μl methanol and, after centrifugation at the same speed 
and temperature for 10 min, the supernatant was transferred to a HPLC vial. Samples from the 
supernatant of the aqueous phase contained the concentration of the desired API released from the 
formulation at a specific time (A sample). The pellet phase was redispersed in 500 μl methanol after 
mixing and sonication for 20 min and the suspension was subsequently centrifuged at the same 
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speed and temperature for 10 min. The supernatant was analysed as the P sample, which 
represented the amount of the fenofibrate remaining in the liposomal formulation. The recovery of 
Fenofibrate in the collected samples was quantified using HPLC. The chromatograms were 
analysed using Chromeleon software. Immediately after each sampling for A and P samples, lipase 
activity was inhibited with a 4-bromobenzeneboronic acid solution (Müllertz et al. 2010). 
2.11 In vivo pharmacokinetics 
The impact of different liposomal formulations on the bioavailability of Fenofibrate was 
investigated. Pharmacokinetic (PK) studies on rats were performed for orally (p.o.) administered 
suspensions of fenofibrate with different types of phosphatidylcholine (EPC and Soluthin S 90). 
The probe sonication method was used to form the lipid vesicles. A pulsed duty cycle of 3 min on/7 
min off was used with a power delivery of 80% for 10 min. The sample vial was kept in a 
temperature-controlled water bath (4°C) to prevent heat damage. Subsequently, after liposome 
preparation, the size and dispersity of samples were evaluated using a Zetasizer. Table 8 shows the 
composition of the different liposomal formulations used for rat studies.  
 
Table 8. The composition of the different liposomal formulations prepared by probe sonication method for 
the in vivo pharmacokinetic purposes. 
Samples Type of PC Fenofibrate %(W/W) Gelatine 
S_90_0% Soluthin S 90 4% 0 μg in 1 mL PBS 
S_90_20% Soluthin S 90 4% 200 μg in 1 mL PBS 
EPC_0% Egg PC 4% 0 μg in 1 mL PBS 
EPC_20% Egg PC 4% 200 μg in 1 mL PBS 
 
 
Healthy male Wistar rats of approximately 300 g in weight (Charles River, Sulzfeld, Germany) 
were housed in cages without food and free access to water, but the water was removed 12 hours 
prior. to administration and replaced 3 hours after dosing. The holding. and study areas had 
automatically controlled light cycles. (12 h light/12 h dark), temperature. (23 ± 1◦C) and humidity. 
(60 ± 10%). Animals were weighted prior. to administration and body weights of 240−320 g were 
registered. 
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The oral formulations were administered by gastric gavage. The dose of fenofibrate was 2.1 mg/kg 
(0.006 mmol/kg) in accordance with the clinical dose (145 mg for a 70 kg adult) (Buch et al. 2009; 
Zhu et al. 2010). To apply 2.1 mg/kg of fenofibrate per rat by gavage, 1 mL of the formulation was 
administered to each animal. Therefore, 0.63 mg of fenofibrate or 15.75 mg of the 4% fenofibrate 
formulation was prepared in 1 mL of PBS with or without gelatine. 
Each study group consisted of two animals and received one of the formulations. At seven time 
points, blood samples were taken from each animal. The sampling times were 0, 0.5, 1, 2, 3, 6 and 9 
hours. Blood samples were collected from the retro-orbital venous.plexus. The blood samples were 
collected in heparin-coated blood collection tubes (Microvette§R 200). Blood cells were separated 
by centrifugation at 1000 × g for 10 min in an Eppendorf  centrifuge 5413C (Eppendorf, Hamburg, 
Germany) and the resulting plasma samples were stored at −80°C and analysed for fenofibric acid 
by HPLC (Labor Limbach, Heidelberg). After the last sampling time, the rats were sacrificed by 
CO2 asphyxia. 
 
2.12 Data and statistical analysis 
The achieved results are provided as arithmetic means ± standard deviation unless otherwise 
indicated. The statistical significance was checked through the two-tailed Student’s t-test in 
Microsoft Excel software. 
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3. RESULTS AND DISCUSSIONS 
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3.1 Preparation Method 
Four different production methods were used to prepare the liposomal formulation. The 
preparation methods were assessed by determining the range of the size and polydispersity of 
the produced particles. Schubert refers to a PDI of less than 0.2–0.3 as a homogenous system, 
which was applicable for this study (Schubert & Müller-Goymann 2005). The characteristics of 
the liposomal particles are briefly summarized in Table 9. 
 
Table 9. Preparation methods and characterization of size and size distribution (n=3, mean ± SD). 
Production method Size (nm) PDI 
Ball milling 157.4± 49.5 0.323± 0.096 
Extruder 119.6± 2.7 0.057± 0.009 
Probe sonication a 159.4± 27.7 0.305± 0.063 
DAC b 132.2± 12.6 0.125± 0.02 
a Probe sonication for 10 min, 80% sonication intensity, 3s pulse on/7s off 
b DAC for 30 min, speed of 3540 rpm 
 The liposome samples were prepared by milling the mixture for 30 min at a frequency of 30 Hz 
in 10-mL grinding jars containing ten 2-mm stainless steel balls in an oscillatory ball mill 
(Mixer Mill MM400, Retch GmbH & Co., Haan, Germany) located in a cold area (+6 °C). 
Although the produced liposomes were within an acceptable range in terms of size and size 
distribution, the final product was rejected as a grey layer of dirt had formed on the top of the 
samples after dilution of the final product. This interfering layer was formed due to interactions 
between the metal beads and the oily compositions, despite the beads being thoroughly washed 
using methanol. 
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a) b) c) 
Figure 14. Ball milling machine(a), liposome produced by ball milling (b), and diluted liposomes (c). 
The lipid extrusion technique was used to form the liposomes. The lipid suspension 
(concentration of 0.65% (W/V)) was passed through a polycarbonate filter (1.0 µm pore size) 
for 10 cycles under a nitrogen gas flow. The resulting liposomes were of ideal size and 
dispersity, but in addition to being highly time consuming, the main limitation of this method 
was that the final suspension was overly diluted as a result of a lack of lipid after filtration, 
rendering the output unsuitable for further experiments (particularly the animal experiments). 
Therefore, extrusion was also removed from the list of preparation methods. 
  
a) b) 
Figure 15. Extrusion machine (a) Liposome suspension produced by extruder (b). 
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Based on the diameter size and PDI described on Table 9, DAC was considered the optimal 
method for preparing liposomal samples, but the speedmixer device was not always accessible 
and due to this access restriction, the probe sonication method was also a suitable and 
alternative method to prepare samples as it produced liposomes within the normal range of size 
and distribution. 
Additionally, an evaluation method was used to determine the threshold level of liposomes for 
loading the poorly water-soluble drug, fenofibrate. To achieve this, different concentrations of 
fenofibrate-loaded liposomes were prepared by DAC to determine the optimal concentration. 
The concentrations ranged from 0% FF (0 g fenofibrate, 40 g cholesterol, 60 g EPC) to 1.5% FF 
(1.5 g fenofibrate: 38.5 g cholesterol: 60 g EPC) to 22.5% FF concentration (22.5 g fenofibrate: 
17.5 g cholesterol: 60 g EPC). Figure 16 illustrates the size (diameter) and size distribution 
characterization of liposomes at different concentrations. The figure shows a clear increase in 
size and polydispersity after 6.5% FF, which indicates that the 4% FF concentration may be 
considered as the optimal concentration due to its size and dispersity range. 
 
a) 
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b) 
 
 
Figure 16. Characterization of liposomal particles in terms of a) size (diameter) and b) size distribution (n=3, 
mean ± SD). 
 
3.2 Particle Size and Morphology 
Liposomes were prepared using DAC according to Table 10. The samples were divided into two 
groups: the first group used EPC as the phosphatidylcholine while the second group used Soluthin 
S 90. Some samples contained gelatine (which it is believed to increase the viscosity outside and 
inside the liposomes) to evaluate its effect on the stability of liposomes. In the preparation method, 
different concentrations of gelatine were added to the PBS buffer. The size and size distribution of 
the prepared liposomes were characterized using a Nano ZS Zetasizer. These characterized 
formulations were also used to determine the entrapment efficiency, Cryo_EM, in the in vitro 
lipolysis study.  
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Table 10. The list of the prepared liposomes contents 
Samples EPC/S90 
Concentration (gr) 
Cholesterol 
Concentration(gr) 
Fenofibrate  
Concentration(gr) 
Gelatine  In D-PBS 
Blank_0% Gel 60 40 0 0 µg/1 mL PBS 
Blank_15% Gel 60 40 0 150 µg/1 mL PBS 
Blank_20% Gel 60 40 0 200 µg/1 mL PBS 
2.5FF_0% Gel 60 37.5 2.5 0 µg/1 mL PBS 
2.5FF_15% Gel 60 37.5 2.5 150 µg/1 mL PBS 
2.5FF_20% Gel 60 37.5 2.5 200 µg/1 mL PBS 
4FF_0% Gel 60 36 4 0 µg/1 mL PBS 
4FF_15% Gel 60 36 4 150 µg/1 mL PBS 
4FF_20% Gel 60 36 4 200 µg/1 mL PBS 
 
 
a) 
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b) 
Figure 17. The size (a) and PDI (b) of liposomes prepared by DAC (n=3, mean ± SD). 
 
Figure 17 shows an acceptable size range of 127–156 nm of liposomes produced using either 
EPC or S 90. In the case of polydispersity, the resulting liposomes indicate a homogenous system 
as the reported PDI is always less than 0.156 (Schubert & Müller-Goymann 2005). It should be 
noted that both EPC and S 90 liposomes had a relatively similar range of size and distribution 
(considering the standard deviation). In a parallel study, probe-sonicated liposomes were 
characterized in terms of size and size distribution. Figure 18 illustrates the range of size and PDI 
of liposomes prepared by sonication method that was considered acceptable (167–190 nm for size 
and 0.234–0.285 for PDI) for further use. 
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a) 
 
b) 
Figure 18. The size and PDI liposomes prepared by probe sonication (n=3, mean ± SD). 
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Based on these results, DAC was selected as the optimal preparation method for liposomes, with 
probe sonication designated as an alternative method in case of speedmixer access restriction. The 
characterization of the physical features of liposomes was followed by Cryo-EM experiments to 
obtain more precise morphological information on the stability of liposomes formed in the presence 
and absence of gelatine.  
 
a) 
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b) 
Figure 19. Cryo_EM images of the liposomal samples a) without gelatine, b) matrix liposomes containing 
gelatine. 
 
 Cryo-EM was employed to observe the morphology of liposomes prepared in either PBS (control) 
or gelatine dissolved in PBS as shown in Figure 19. Cryo-electron micrographs showed that the 
liposomes were mainly multilammellar and similar in size and shape, independent of whether they 
were prepared in the presence or absence of gelatine. Therefore, according to the images obtained 
by Cryo-EM, it was concluded that gelatine did not have an effect on the size or shape of vesicular 
liposomes and, consequently, that it might not have a strong effect on the stability or bioavailability 
of the samples. However, Cryo-EM might not have been the most suitable approach to determine 
the effect of gelatine on liposomal formulation. Further in vitro experiments followed by in vivo 
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pharmacokinetic studies were therefore needed to evaluate the Cryo-EM images for supplementary 
experimental results. 
 
3.3 Determination of Entrapment Efficiency 
Entrapment efficiency (%) of the sonicated liposomes was determined (Table 11) for liposomes 
loaded either with EPC or S 90. 
Table 11. Entrapment efficiency (%) and loading capacity (%) (n=3, mean ± SD). 
Sample %EE EPC_liposomes %EE Soluthin S 
90_liposomes 
2.5% w/w FF_ 0% Gelatine 97.42± 1.07 98.43± 1.76 
2.5% w/w FF_ 15% Gelatine 97.21± 2.11 96.42± 1.98 
2.5% w/w FF_ 20% Gelatine 95.35± 1.72 95.98± 2.32 
4% w/w FF_ 0% Gelatine 98.12± 1.9 99.04± 1.03 
4% w/w FF_ 15% Gelatine 95.15± 2.05 97.32± 1.93 
4% w/w FF_ 20% Gelatine 96.41± 2.14 97.06± 2.06 
 
As shown in Table 11, the %EE decreased as the concentration of gelatine in the liposome matrix 
increased, however, this did not result in significant difference in entrapment efficiency between the 
liposomes produced from EPC and S 90 (considering the standard deviations). The entrapment 
efficiencies were markedly increased, representing a high level of fenofibrate encapsulation in the 
lipid layer. Fenofibrate has a very high affinity towards the lipid phase because of its high 
lipophilicity and this was expected for the poorly water-soluble drug e.g., fenofibrate. During 
liposome preparation, fenofibrate is incorporated within the lipid film, and subsequently in the lipid 
layer of liposomes, resulting in a very low amount of fenofibrate in the aqueous phase. The high 
affinity towards the lipid phase has also been observed for other lipophilic drugs (Sharma et al. 
2010; Ekambaram & Sathali 2011). 
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3.4 X-ray Powder Diffraction 
An assessment of the physical states of prepared liposomes was carried out XRPD to determine 
crystal formation. An XRPD peak indicates the crystalline nature at a particular value in the 2θ 
range. The XRPD patterns of crystalline fenofibrate and of blank and fenofibrate-loaded liposomes 
(various concentrations) are shown in Figure 20. In this study, the pure drug fenofibrate showed 
several characteristic reflections of crystalline fenofibrate. The size and sharpness of XRPD peaks 
are primarily dependent on crystal size. The pattern of crystalline fenofibrate was in accordance 
with that reported previously (de Waard et al. 2010). For liposomes, no crystal pattern was detected, 
even at high concentrations.  
 
Figure 20. X-ray powder diffraction patterns of fenofibrate loaded liposomes containing a) 0% fenofibrate 
(Blank sample), b) 4% fenofibrate, c) 20% fenofibrate, and crystalline fenofibrate. 
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This indicates the existence of the amorphous form of fenofibrate or even molecular dispersion, 
which has faster dissolution than the crystalline form (Khan et al. 2016). As per liposomes with 
high concentration of fenofibrate, no crystalline was formed to reduce the rate of drug dissolution. 
Nevertheless, taking the results of Section 3.1 (Figure 16) into consideration, it was not possible for 
liposome preparation to go higher than 4% concentration due to the appearance of deformation 
(bigger size and higher PDI) after the desired concentration. 
3.5 Dissolution 
 In most research settings, the dissolution apparatus is widely used to model in vitro drug digestion 
and release. The dissolution profiles of EPC-liposomes prepared by DAC were evaluated, and are 
summarized in this section. For this purpose, the USP II (paddle) apparatus was used as a 
compendial method for dissolution testing, following the protocols from the pharmacopoeias (The 
United States Pharmacopeia and National Formulary 2014b). To simulate the gastrointestinal 
environment, three types of media with different properties were used: Simulated Intestinal Fluid 
(SIF), Fasted-State Simulated Intestinal (FaSSIF, pH 6.5) and Fasted-State Simulated Gastric Fluid 
(FaSSGF). The techniques used to evaluate the quality of liposomes were different, and were 
selected according to the objective of each experiment. Furthermore, the light-scattering method 
was considered the optimal approach to assess the physical states of particles in term of size 
(diameter) and polydispersity. 
 
3.5.1 Liposome release 
The dissolution behaviour of 100 mg of solidified vesicular phospholipid gels (VPGs) from DAC 
was evaluated using a paddle dissolution apparatus. For this purpose, SIF was used as the 
dissolution medium and EPC was the phosphatidylcholine used to prepare the liposomes. The 
physical states of collected samples were assessed by DLS using a Zetasizer Nano ZS. The derived 
count rate among the Malvern parameters is an effective parameter to track the concentration of 
liposomes converting from the semisolid formulation into free liposomes. Since the amount of 
scattered light is related to the size and number of particles present in a sample, the derived count 
rates or absolute light scattering in kilo counts per second (kcps) may represent the presence of 
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nanoparticles in the sample (Wallace et al. 2012). Figure 21 illustrates the release of liposomes from 
different concentration of the semisolid formulation. 
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c) 
Figure 21. Dissolution behaviour of EPC- liposomes containing different concentration of gelatine in 
simulated intestinal fluid pH 6.8 and 37 °C for blank sample (a), 2.5%FF (b), and 4%FF (c). Scattering 
intensities (in a correlation with particle concentration) were measured with a Zetasizer instrument and are 
expressed as derived count rate (kcps). Each data point is the mean ± SD of three independent experiments. 
 
As shown in Figure 21, the amount of liposome released from the solidified VPGs increased over 
time. A negative correlation was detected between the rate of liposome release and gelatine 
concentration. The more gelatine that was incorporated into the liposomes, the lower the speed of 
dissolution a specific time point. 
Liposomes prepared without gelatine were completely dissolved in the media, while for 
formulations containing 15% gelatine, a constant quantity of liposomes was observed after 100 min, 
indicating the capacity of the desired semi-solid formulation to release liposomes. The solidified 
formulation containing 20% gelatine consistently dissolved in SIF within 150 minutes, and thus had 
the potential for use as a sustained-release formulation. By comparing the level of the derived count 
rate for different concentrations of gelatine from Figure 21, gelatine can be taken as occupying 
some space in the solidified matrix liposomes as the initial concentration was identical for all 
prepared samples. In addition, the size (diameter) and polydispersity index of liposomes released 
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from the solidified dosage form were evaluated. Figure 22 illustrates the physical states of the 
examined liposomes. 
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c) 
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e) 
 
f) 
Figure 22. Size and poly dispersity index (PDI) of EPC-liposomes containing different concentration of 
gelatine in simulated intestinal fluid pH 6.8 and 37 °C for blank sample (a, b), 2.5%FF (c, d), and 4%FF (e, 
f). (n=3, mean ± SD). 
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The size of particles detected by DLS decreased over time and reached approximately 200 nm in 
the first 20 minutes. After 40 minutes of dissolution, samples were stable in size, ranging from 169–
210 nm. In the case of polydispersity, samples were also stable after 40 minutes and were 
consistently lower than 0.3, indicating homogenous and within-range liposomal vesicles.  
 
3.5.2 Drug release 
A stability study of fenofibrate-loaded EPC liposomes prepared by DAC was carried out in FaSSIF 
(pH 6.5) and FaSSGF (pH 1.6) biorelevant media. FaSSIF medium was used to simulate upper 
small intestinal conditions while FaSSGF medium was used to represent fasting conditions in the 
stomach.  
Dissolution profiles obtained in FaSSIF using the USP paddle apparatus are shown in Figure 23. 
The percentage of fenofibrate released from the formulation is marked by dots in different colours. 
Each set of experiments was run for 3 hours, and the quantity of drug released from liposomes 
containing 145 mg fenofibrate was determined.  
 
Figure 23. Mean dissolution profiles ± SD (n=3) of different concentrations of EPC-liposomes in Fasted-
State Simulated Intestinal Fluid (FaSSIF, pH 6.5), using the USP paddle apparatus. 
 
   63  
 
 
The results show clear differences in the dissolution profiles obtained for samples prepared in the 
absence or presence of gelatine. It was observed that around 40% of fenofibrate was released from 
EPC liposomes with different concentrations after 180 min. Figure 23 clearly depicts a steeper slope 
for the release of drug from liposomes without gelatine (regardless of the loading concentration), 
while liposomes containing gelatine showed linear dissolution profiles, representing a slower rate of 
release. The dissolution profile for non-gelatine-containing formulations was faster, with more than 
80% of drug dissolved within the first 30 min. A statistically significant difference (p < 0.05) was 
observed between the amounts of fenofibrate dissolved after 30 min from gelatine-based liposomal 
formulations compared with non-gelatine formulations, although all had released the same amount 
of drug after 2 hours. Liposomes containing the same quantity of gelatine showed the same drug 
release profile over time. 
Furthermore, the physical states of formulations were evaluated to obtain a better understanding of 
the fate of liposomes in the intestinal. The size and polydispersity of the tested formulations is 
shown in Figure 24. 
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b) 
Figure 24. Size (diameter) (a) and polydispersity index (b) of different concentrations of EPC-liposomes in 
Fasted-State Simulated Intestinal Fluid (FaSSIF, pH 6.5), using the USP paddle apparatus. (n=3, mean ± 
SD). 
 
When the physical states of fenofibrate-loaded liposomes were measured in FaSSIF (pH 6.5) 
biorelevant medium, the formulations clearly showed relatively stability with respect to size, 
regardless of the loading concentration. This part of the study on dynamic particle size variation 
showed a PDI of less than 0.22, which implies to be rather in range and stable size distribution. 
These results represent the ability of formulations to maintain their integrity in simulated conditions 
of the upper small intestinal. 
The harsh, acidic environment of the stomach was simulated by exposing the prepared formulations 
to FaSSGF (pH 1.6) in a paddle apparatus model. The dissolution profiles of the tested samples are 
illustrated in Figure 25. 
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Figure 25. Dissolution profiles of different concentrations of EPC-liposomes in Fasted-State Simulated 
Gastric Fluid (FaSSGF, pH1.6). (n=3, mean ± SD). 
 
Dissolution results using FaSSGF as the dissolution medium show clear differences in the amount 
of drug released from the samples compared with the dissolution data using FaSSIF as the 
dissolution medium. However, the liposomal formulations prepared in the absence and presence of 
gelatine showed approximately similar dissolution profiles for the release of fenofibrate, as 
formulations without gelatine released their incorporated drug at a faster rate than those containing 
gelatine. Nevertheless, it is clear from Figure 25 that the percentage of drug released from the 
formulations prepared without gelatine was relatively higher, ranging from 50% to 70%. To obtain 
a better overview of the fate of liposomes, dynamic light scattering was used to evaluate the 
physical features of particles following their exposure to the acidic FaSSGF medium. The size and 
PDI of FaSSGF-exposed liposomes are shown in Figure 26. 
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a) 
 
b) 
Figure 26. Size (a) and Polydispersity index (b) of different concentrations of EPC-liposomes in Fasted-State 
Simulated Gastric Fluid (FaSSIF, pH 6.5), using the USP paddle apparatus. (n=3, mean ± SD).  
 
As Figure 26 illustrates, the particle size in FaSSGF medium clearly increased for all of the DAC-
prepared formulations over time, as did the PDI. From the dynamic particle size, as well as by 
increasing the amount of released drug in the dissolution profile in FaSSGF, it was suggested that 
the harsh, acidic conditions of FaSSGF medium might lead to the disruption of liposomal features. 
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By increasing the size of particles, aggregation in the vesicular liposomes was demonstrated, while 
fenofibrate – as the incorporated drug – is released from the formulations.  
The dissolution data for the prepared formulations in different biorelevant media (FaSSIF and 
FaSSGF) provided some general information about the fate of liposomes. In both media, non-
gelatine-containing formulations released fenofibrate faster, with approximately 80% released after 
the first 30 minutes and more than 95% of drug released after the first hour, whereas gelatine-
containing formulations released more than 95% of fenofibrate after 2 hours.  
A comparison of the results from the last hour of dissolution testing in biorelevant media for 
gelatine-containing liposomes showed that formulations were relatively more capable of releasing 
drug if they had been prepared with a higher fenofibrate loading concentration. Moreover, after 
comparing the behaviour of gelatine and non-gelatine samples, it could be concluded that gelatine 
functions as a limiting factor for liposomes to release the incorporated drug at a constant rate, and 
this could be related to the ability of gelatine to increase the density inside and outside the layers of 
vesicular liposomes. This finding represents an advantage of gelatine-containing liposomes for use 
in sustained-release formulations. 
The results from the dissolution studies in biorelevant media showed that, for the last 90 minutes of 
the experiment, all formulations released the same amount of drug, and it is clear from the slope of 
the curves shown in Figure 23 and Figure 25 that all of the samples did not release a significant 
quantity of drug from the formulations for this period of time.  
In FaSSGF medium, the particle size increased for all formulations over time, as did the PDI, 
whereas in FaSSIF medium, both remained relatively constant, suggesting that the liposomes were 
more stable in an intestinal environment compared with the low pH conditions of gastric fluid. 
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3.6 Storage Stability 
To investigate the physical state of fenofibrate-loaded liposomes over time, a DLS was performed 
for selected formulations. Figure 27 represents the stability of EPC liposomes prepared by DAC in 
terms of size and PDI over 3 months.  
 
 
a) 
 
 
b) 
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c) 
 
 
d) 
Figure 27. Stability of different samples in size (a and b) and dispersity (c and d) at 4 and 25 °C, 
respectively. 
 
All preparations showed acceptable stability over 3 months. The size and polydispersity of the 
liposomes increased slightly in this period, and a constant increase in size of liposomes prepared 
without gelatine compared with liposomes prepared using gelatine was observed (Figure 27). An 
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insignificant (p>0.05) increase in particle size and distribution was detected between different 
concentrations, indicating that the content of the formulation did not affect liposome size. 
3.7 Dynamic In Vitro Lipolysis  
To study the digestion and solubilisation of drug formulations in biorelevant media simulating the 
gastrointestinal environment, an in vitro lipolysis model with the continuous addition of calcium 
was used (0.5 mM final concentration of calcium). In this study the in vitro lipolysis model based 
on the method described by Zangenberg et al., with some modifications (Zangenberg et al. 2001a; 
Zangenberg et al. 2001b). The lipolysis system consists of two different compartments: the gastric 
(pH 4) part and the intestinal (pH 6.5) part, which were connected by a transferring pump. An auto-
titrator system was incorporated to ensure lipase activity by maintaining the pH. As described in 
section 2.10.3, the experiment was run for 1 hour and samples were collected at 5, 15, 30 and 60 
mins. The collected samples were subjected to ultracentrifugation at high speeds to overcome 
separation challenges, resulting in T, A and P samples. The T sample represented a total sample, a 
mixture of aqueous and oily phases containing released and unreleased sample. To evaluate the 
accuracy of the developed model and the validity of the analysis method, the amount of T sample 
from the experiment was compared with the expected amount from a theoretical analysis, and the 
results are shown in Figure 28.  
The A (aqueous) sample includes the amount of drug in the aqueous phase, which is the fenofibrate 
released from the lipid-based formulation and diffused into the aqueous phase of the lipolysis 
medium. The P (pellet) sample represents the amount of drug detected in the pellet after 
ultracentrifugation. The pellet contains only the oily phase, and therefore includes undissolved 
liposomes. The liposomal formulations were prepared with different phosphatidylcholine 
compositions, namely E-PC, S-PC or Soluthin S 90, both with and without gelatine. The theoretical 
concentrations were determined according to the initial concentration of drug in the formulation 
distributed in media, the speed of the transferring pump and the time of sampling. Because a 
specific amount of drug was removed from the entire volume after each sampling, this amount was 
also accounted for. Furthermore, the amount of titrating buffer added to the experimental medium 
led to modifications in the volume, which were also noted. The dynamic particle sizes of prepared 
formulations are shown in Table 12 and as liposome ranges in terms of size and PDI. 
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Table 12. Size and distribution of probe sonicated liposomes prepared for lipolysis model (n=3, mean ± SD). 
Samples 4%FF_0%_ 
EPC 
4%FF_20%_ 
EPC 
4%FF_0%_ 
SPC 
4%FF_20%_ 
SPC 
4%FF_0%_  S 
90 
4%FF_20%_ S 
90 
Size (nm) 162.8± 12.6 173.4±9.2 146.7±12 151.4±9.8 141.9±14.1 144.2±6.6 
PDI 0.281±0.016 0.262±0.023 0.282±0.018 0.278±0.023 0.264±0.025 0.251±0.027 
 
 
3.7.1 Drug recovery 
The dissolution experiments were carried out to determine the release of fenofibrate from the respective 
formulation and shown in Figure 28. 
 
a) 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0 10 20 30 40 50 60
C
o
n
c.
 (
m
g/
m
L)
Time (min)
4%FF_0% EPC
Experimental Conc.
Theoric Conc.
   72  
 
 
 
b) 
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d) 
 
 
e) 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0 10 20 30 40 50 60
C
o
n
c.
 (
m
g/
m
L)
Time (min)
4%FF_20%_SPC
Experimental Conc.
Theorica Conc.
0
0.05
0.1
0.15
0.2
0.25
0.3
0 10 20 30 40 50 60
C
o
n
c.
 (
m
g/
m
L)
Time (min)
4%FF_0% S 90
Experimental Conc.
Theoric Conc.
   74  
 
 
 
f) 
Figure 28. Recovery of total (T) sample in lipolysis model: Comparing the theoretical concentration and total 
concentration of Fenofibrate in tested samples of liposomes containing different PC compositions: EPC (a 
and b), SPC (c and d), and S 90 (e and f), with (right side) and without (left side) gelatine. 
 
The results presented in Figure 28 show that there was no significant difference (p< 0.05) between 
the expected theoretical concentration and the experimental concentration from the lipolysis model, 
except for samples withdrawn after 30 minutes. This may have resulted from experimental errors 
occurring during transfer between the gastric and intestinal parts, or it might have been caused by 
uneven distribution of the intestinal suspension by the stirrer. The gastric compartment contained 10 
ml of a mixture of media and sample and, after 20 minutes, the entire volume was transferred to the 
intestinal part using the pump (0.5 mL/min). A comparison of the theoretical concentrations of 
samples with the experimental data showed the effectiveness of the gastrointestinal compartment as 
well as verifying that the analytical methods were suitable for use in subsequent lipolysis 
experiments. 
The next step was to assess the T, A and P samples of the in vitro lipolysis model. Given that the T 
sample contained both the oily and aqueous phases, the correlation between the T sample and the 
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sum of the A and P samples was determined to evaluate the accuracy of the separation methods. 
Figure 29 illustrates the total recovery of fenofibrate in both the aqueous and non-aqueous phases.  
 
Figure 29. Total recovery of fenofibrate (%) in the pellet and aqueous phase (A+P/T) during one-hour in 
vitro lipolysis (mean ± SD, n=3). 
 
To separate the aqueous and pellet phases, all collected samples were ultra-centrifuged. The pellet 
phase in the apparatus consists of undigested/partially digested liposomes and calcium soaps of free 
fatty acids (Larsen et al. 2011). As expected, the amount of fenofibrate in the pellet phase (P 
sample) followed a drug concentration trend opposite to that in the aqueous phase (A sample). The 
total fenofibrate recoveries for all prepared samples (both phases combined) upon the lipolysis of 
liposomes were almost identical and ranged from 80% to 90%. However, theoretically, to the 
recovery should add up to 100%. Although the amount of drug withdrawn in each sampling was 
accounted for in the calculations, some portion of the drug was clearly missed at one or more stages 
of the experiment. This represents a slight decrease in the total content of fenofibrate during the 
different steps of in vitro lipolysis, and may be the result of transferring the pellet phase to the 
analysis step (ultracentrifugation, re-dispersion and, more importantly, HPLC analysis preparation). 
The resulting pellet is sticky and compact, with a smooth top layer that makes further transfer 
somewhat difficult and provides an explanation for the inability of total fenofibrate content to reach 
100% recovery. This also explains the rather high variation observed in the recovery of the pellet 
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phase. Nevertheless, a recovery of 80%–90% was considered acceptable, as the entire experiment 
comprises different steps for sampling, separation, purification and, finally, analysis. An accurate 
experimental method is highly recommended for the transfer and determination of the recovery of 
drug in the pellet phase. 
In order to obtain a better understanding of the source of missing sample in these experiments, and 
the reason why 100% total recovery was not achieved, the concentrations of different phases were 
evaluated from a different perspective. In this part of the study, the amount of released drug was 
compared relative to two different elements: the total amount of incorporated drug from the T 
sample and the sum of the amount of drug in the pellet and aqueous phases. Figure 30 illustrates the 
release patterns of liposomal samples, where the percentage of drug released from the liposomes for 
each formulation was calculated as A/T (left side) and A/A+P (right side). The release pattern 
according to A/T represents the amount of drug in the aqueous phase (A sample) to the total amount 
of the drug (T sample). The second release pattern was according to A/A+P represents the released 
fenofibrate in the A sample to the amount of the drug existing in both the supernatant and pellet 
phases (A+P samples).  
 
a) 
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b) 
 
 
c) 
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d) 
 
 
e) 
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f) 
Figure 30. Release profile (%) of fenofibrate from liposomes with different compositions according to the 
A/T (left side; a, c, and e) and A/A+P (right side; b, d, and f), (mean ± SD, n=3). 
 
Although both forms of release profile illustrate an overall increase in the amount of fenofibrate in 
the aqueous phase as lipid digestion proceeds, the right-side profiles (A/A+P) show more 
fenofibrate release (%). Since these results were obtained in the same experiment (each right- and 
left-side figures), this difference represents a slight decrease in the denominator of the second 
equation (A+P). To obtain further information on the reason for this dissimilarity in concentration, a 
supplementary experiment was performed. To overcome the issue of pellet recovery, the pellet re-
dispersion solvent was first examined. Methanol was used to dissolve the pellet part remaining after 
ultracentrifugation, especially the oily part consisting of undigested/partially digested liposomes. 
After comparing the results for re-dispersing the pellet in methanol, acetonitrile, n-hexane or diethyl 
ether, or a mixture of these solvents (data not shown), methanol was selected as the most suitable 
solvent for re-dispersing the lipophilic pellets.  
The solid phase of the pellet was also evaluated by XRPD, and the resulting data are shown in 
Figure 33Since fenofibrate is released slowly from liposomes, it is unlikely that precipitation occurs 
in the pellet phase after dispersal and lipolysis. After carefully repeating and verifying all of the 
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steps of pellet sample preparation for HPLC analysis, an experimental error was visually detected. 
After ultracentrifugation, no distinct boundary was observed between the pellet and the aqueous 
phase, and the upper layer of the pellet phase was partially fixed. Some parts of the pellet phase 
were therefore missing after separation and removal of the aqueous phase from the solid phase. Due 
to this unavoidable error, fenofibrate recovery (%) was calculated according to the total samples 
(A/T) to obtain more accurate results. Figure 31 shows a better representation of the release profile 
for all formulations. 
 
 
Figure 31. Release profile of fenofibrate (%) of the all of the formulations with three kinds of PCs, with and 
without gelatine (mean+ SD, n=3). 
 
It was obtained from Figure 31 that, for the different types of liposomes, a general trend (regardless 
of the type of phosphatidylcholine and amount of gelatine) towards increased release of fenofibrate 
from the formulations in the aqueous phase was observed as the digestion process continued over 
time. As shown, there was no significant difference between the different types of prepared 
formulations in terms of the release profile (%) of fenofibrate from liposomes into the aqueous 
phase of the lipolysis environment. This may be attributable to the small size of liposomes, which 
offers a greater surface area for releasing the incorporated drug, or to the pattern of drug distribution 
in the liposome shell. As described previously, liposomes contain an aqueous and a non-aqueous 
compartment. Lipophilic drugs such as fenofibrate have an affinity to partition from hydrophilic 
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core into the lipid surface of liposomes (Müller et al. 2000; Muchow et al. 2008). These specific 
characteristics correlate with the amount of fenofibrate solubilized in the aqueous phase in the 
lipolysis study. Since all experimental formulations were prepared with the same size range and 
similar distribution affinity, they all showed the same drug-release profile. As the digestion process 
occurs over time, the fatty acids and other lipid digestion products released together with bile salts 
and phospholipids in the biorelevant lipolysis media facilitate the solubilisation of precipitated 
drugs by forming micelles (Dahan & Hoffman 2008). 
 
Although fenofibrate was released over time from the liposomal formulation via a lipolysis 
process, the release profile, which indicates drug solubilisation into the aqueous phase, did not 
approach 100%. The amount of fenofibrate solubilized into the aqueous phase at 60 min ranged 
from 42% to 48%. This may have been cause by the very low solubility (5.41 μg/mL ± 0.12 
μg/mL) of fenofibrate in the biorelevant medium at 37°C (Borkar 2012). Furthermore, the 
formation of micelles helps to precipitate fenofibrate, but a burst release due to the previous 
reasons (small size and shell partitioning) would cause the initial precipitation of fenofibrate. In 
addition to these two explanations, running the lipolysis model for 60 minutes may have been 
insufficient to observe a complete digestion process. Performing lipolysis for a longer duration 
may provide further information about the digestion process and release profile of experimental 
samples after 1 hour. 
 
3.7.2 NaOH titration 
During the in vitro lipolysis experiments, lipid digestion occurs and this process produces free fatty 
acids that decrease the pH of the intestinal compartment. To overcome this challenge and by 
maintaining the pH of the intestinal compartment within the pH range of 6.5, an auto titrator was 
used to allow the lipolysis system to eliminate any pH changes occurring due to digestion in the 
medium by adding NaOH solution (0.5 M). The amount of titrated NaOH correlated reasonably 
with lipid digestion and, therefore, the drug content in different phases. Figure 32 illustrates the 
amount of NaOH (mmol) added during the 60 minutes of assessment of in vitro lipid digestion in 
the intestinal compartment. In the early stage of the intestinal evaluation of in vitro lipolysis, an 
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initial lipid concentration from the gastric compartment is observed due to the low pH conditions 
(pH 4), as well as the availability of gastric enzyme in the mixture which influences lipid digestion 
and increases the free fatty acids in the experimental media. This leads to a pH reduction, requiring 
the auto-titrator system to add an adequate volume of NaOH solution. This leads to an additional 
volume of aqueous suspension in the intestinal compartment and subsequently decreases the final 
lipid concentration for consideration. A blank lipolysis (without formulation) experiment was 
carried out to determine the exact amount of NaOH added to the intestinal compartment for titrating 
the FAs released from the liposomal formulation due to lipid digestion and pH reduction. 
 
 
Figure 32. Addition of NaOH (mmol) during hydrolysis of the lipids present in liposomes in the in vitro 
lipolysis model simulating the rat conditions. The data are presented as mean ± SD (n=3).   
 
Figure 32 illustrates the intended amount of NaOH (mmol) added after considering the blank 
lipolysis data. The amount of FAs released from the liposomes corresponded stoichiometrically 
with the amount of titrated NaOH at a ratio of 1:1 and offers an indirect indicator of the kinetics of 
lipid digestion (Dahan & Hoffman 2008). A significant, sharp increase in NaOH titration was 
observed for all formulations within the first 5 minutes upon rapid lipid digestion, which was due to 
the exposure of the mixture to pancreatin enzyme and bile salts. However, after 5 minutes, as the 
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capacity of the intestinal enzyme decreased and precipitation occurred, free fatty acid production 
and therefore, the acid titration decreased according to the type of phosphatidylcholine formulation. 
EPC- and S 90-prepared liposomes released more free FAs (especially S 90) compared with SPC-
prepared liposomes, and the difference was significant (p<0.05). For SPC-prepared formulations, 
there was a reduced tendency to release FAs after 5 minutes, and it could be concluded that 
although SPC samples, especially SPC_4%FF_0% Gel (SPC prepared liposomes containing 4% 
fenofibrate without gelatine), released more drug during lipolysis (Figure 31), most of the drug 
release (40%) happened in the first 5 minutes of the intestinal step and exclusively at the gastric 
stage. This shows a reduced potency for SPC samples to tolerate the harsh acidic gastric 
environment compared with the other types of phosphatidylcholine formulations. After the first 5 
minutes, a noticeable decrease in NaOH titration was observed. An obvious explanation for this 
occurrence is that although the formation of micelles helps precipitated drugs to solubilize into the 
aqueous phase, due to rapid lipid digestion during the initial exposure to the intestinal environment 
and the presence of lipolysis enzymes, bile salts and other contributing factors, unavoidable 
precipitation occurs in the lipolysis process that saturates the activity of the lipase enzyme. This 
limits the rate of digestion and, subsequently, the production of FAs (Dahan & Hoffman 2008). 
Figure 32 representing the digestion and release of FAs, potentially correlates with the release 
profile of formulations (Figure 31) and supports these data by providing more information on lipid 
digestion and its source. Figure 31 shows the digestion process from 5 minutes after entering the 
intestinal section, while the FA titration graph (Figure 32) completes the digestion process, 
especially the first 5 minutes which is relatively important as it gives more information about the 
previous step (gastric level). The gastric compartment has a low pH and lipolysis enzymes and the 
digestion process mostly initiates from this part of GIT, therefore, it is essential and important to 
have a better understanding about the occurrences in the gastric part. In this study, no statistical data 
was obtained from the gastric section and therefore, the first 5 minutes of the intestinal part helps to 
have a better overview about the lipolysis process in gastric and intestinal part. Moreover, in the 
beginning of intestinal process a rapid lipid digestion occurs as the pancreatin enzyme has a high 
capacity for digestion, information about the first 5 minutes is very important for evaluating the 
formulations. Both figures represent the actual lipid digestion process in the intestinal compartment 
during in vitro lipolysis. 
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3.7.3  Solid phase evaluation 
An assessment of the physical state of the precipitates of fenofibrate during in vitro lipolysis was 
carried out. The resulting data provide more details about the lipolysis process; furthermore, XRPD 
patterns help to explain the in vitro and in vivo data. It has been shown that amorphous precipitation 
has a faster dissolution rate compared with the crystalline form – in the case of amorphous 
precipitation, this implies that drug absorption will not be limited while the crystalline form 
interferes with dissolution by drug precipitation and consequently has a negative effect on 
bioavailability (Khan et al. 2016). From previous studies on the fate of poorly water-soluble drugs 
incorporated into lipid-based formulations, it has been demonstrated that the amorphous 
precipitated form can be detected while running the in vitro lipolysis model (Stillhart et al. 2014; 
Thomas et al. 2014; Thomas et al. 2013). 
The XRPD patterns of the pellet of 4%FF_20% gel_SPC, the pellet, and the blank pellet of 
4%FF_20% gel_S 90 after 60 min of lipolysis were compared with the crystalline form of 
fenofibrate and are shown in Figure 33. The pure fenofibrate drug pattern revealed several 
characteristic indicators of crystalline fenofibrate, which was in agreement with previous powder 
diffraction patterns of the crystal structure of fenofibrate (Heinz et al. 2009). Figure 33 shows that 
the peak positions in XRPD of precipitated fenofibrate available in the pellet clearly did not 
correlate with the crystalline pattern of spiked fenofibrate. This potentially implies that no 
crystalline fenofibrate was formed in the pellets during 1 hour of in vitro lipolysis. Therefore, the 
amorphous form or molecular dispersion with a higher dissolution rate (compared with the 
crystalline form) was available in the pellet and facilities the lipolysis process by increasing the rate 
of dissolution. The powder diffraction shown in Figure 33 strongly correlates with the dissolution 
profile of Figure 31 and supports the achieved information about the release profile of the 
formulations for predicting absorption profiles that were virtually similar for all tested samples. 
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Figure 33. XRPD pattern of pellets obtained after 60 min of lipolysis of the formulations containing a) 
EPC_4%FF_20%Gel, b) SPC_4%FF_20%Gel, c) S 90_4%FF_20%Gel, compared with crystal. 
 
3.8 In Vivo Pharmacokinetics 
The aim of the in vivo pharmacokinetic study was to evaluate the effect of different types of 
phosphatidylcholine on the bioavailability of the formulations. Suspensions of different liposomal 
formulations were orally administered to rats. In order to obtain an overview of the function of the 
lipid digestion model, the correlation between in vitro lipolysis data and in vivo bioavailability was 
investigated. Mean plasma concentration curves following the oral administration of 2.1 mg/kg of 
fenofibrate formulations in fasted rats are shown in Figure 34. 
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Figure 34. Fenofibric acid concentrations in rat plasma (µg/ml) after the administration of various liposomal 
formulations of fenofibrate. Data are presented as mean ± SD (n=2).  
 
The formulations prepared using Lipoid Soluthin S90 yielded higher plasma concentrations of 
fenofibric acid as an active metabolite of fenofibrate compared with the formulations prepared 
using Lipoid EPC. Thereby, no major differences were observed with respect to the addition of 
gelatine to the formulations. 
 
Table 13. Pharmacokinetic parameters of fenofibrate following oral administration of four different 
liposomal formulations (mean ± SD, n=2). 
Samples Size    
(nm) 
PDI Dose 
[mg/kg] 
AUC 
[µg/ml∗h] 
Tmax   
[h] 
Cmax 
[µg/ml] 
S 90_0%Gel. 168±7 0.263±0.018 2.1 48.12±8.32 1.8±0.5 8.53±0.4 
S 90_20%Gel. 176±11 0.298±0.019 2.1 42.67±12.54 1.6±0.7 8.12±0.7 
EPC_0%Gel. 194±21 0.307±0.031 2.1 17.075±4.97 2.1±1.1 2.64±0.3 
EPC_20%Gel. 180±12 0.271±0.023 2.1 21.6±7.26 2.5±1.5 3.29±0.9 
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The AUC for formulations containing Soluthin S 90 was significantly higher (p<0.01) compared 
with that of the EPC_formulations (Table 13), and was clearly distinct from the plasma 
concentration-time curves (Figure 34), thus indicating that the formulations containing Soluthin S 
90 have greater bioavailability. This can be explained by the type of phosphatidylcholine used for 
preparing the samples. Soluthin S 90 is a mixed phospholipid consisting of SPC, acid value, lyso-
phospholipid and calcium, as described in detail in Table 14. Lyso-phosphatidylcholine (LPC) is a 
natural surfactant present in the human gastrointestinal tract and is highly recommended (by the 
FDA) for use in the preparation of drug formulations, especially for liposomal applications (van 
Hoogevest & Wendel 2014). From previous studies, it has been suggested that natural and low-cost 
LPCs are effective in the lymphatic transportation of α-tocopherol (a fat-soluble vitamin) in rats 
(Koo & Noh 2001). The acid value may improve the digestion of the formulation and, more 
importantly, the existence of calcium in the mixture facilitates the digestion process by forming 
calcium FA soaps and removing the oil/water interface. Therefore, each composition of the Soluthin 
S 90 mixture in combination with the different procedures allows the formulation to show effective 
digestion, absorption and bioavailability. 
Table 14. list of the compositions of Soluthin S 90 from lipoid company. 
Compounds Content (%) Methods 
Phosphatidylcholine 87.7 % LC-PL 
Lyso-phosphatidylcholine 2.6 % LC-PL 
Free fatty acids 0.05 % ADC5 
DL-a-Tochopherol 0.1 % ADC5 
Unknown compound (DC) 0.2 % ADC5 
Ethanol 0.3 % ET 
Water 1.4 % USP<921>Ia 
Peroxide 0 POZ 
Acid level 4 % SZ 
Calcium 2.7 % CA 
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On the other hand, no statistical difference was evident observed for formulations containing EPC 
and Soluthin S 90 in the absence and present of gelatine. Although the dissolution experiments 
(Figure 23 and Figure 25) showed a minor difference between formulations containing gelatine and 
those without gelatine in releasing the incorporated drug from the liposomal VPGs, the in vitro 
lipolysis model showed no significant difference between samples containing 0% and 20% gelatine. 
In comparison with the USP model, the in vitro lipolysis model simulates the gastrointestinal 
environment in more detail in terms of composition, pH, molarity, enzymes and the digestion speed 
criteria, as briefly described in section 2.10. Although other research has shown that gelatine can 
increase the bioavailability of liposomes by increasing the viscosity of the inside and outside of 
VPGs (Pantze et al. 2014), from the results of the in vitro and in vivo models, it can be determined 
that gelatine has no functionally positive effect on the fate of liposomes. Additionally, from the 
cryo-EM experiment (section 3.2), the microscopy images showed no significant difference in the 
physical features of both types of fenofibrate-loaded formulations prepared either with or without 
gelatine. Therefore, the microscopy images could be counted as one the evidence that gelatine has 
no influence on the stability and, consequently, the bioavailability of liposomal formulations. 
The AUC and Cmax of the S_90_0% sample was significantly higher (p<0.01) than that of the other 
liposomal formulations, although this difference was not statistically significant in the case of 
S_90_20%. In general, the absence or presence of gelatine had no significant effect on AUC, Cmax 
or Tmax, and this was observed for both EPC- and Soluthin S 90-type liposomal formulations. EPC-
type formulations (EPC_0% and EPC_20%) showed a relatively low AUC and Cmax compared with 
Soluthin S 90 formulations, with lower bioavailability, and EPC formulations therefore show a 
lower treatment effect. No significant difference was observed between the Tmax of the different 
prepared formulations. 
The pharmacokinetic study was based on a study conducted by Anhalt and followed the same 
administration dose (2.1 mg/kg) for each rat (Anhalt 2012). In that study, oral nanocrystal 
formulations were used as a drug carrier for fenofibrate to increase its bioavailability in the oral 
dosage form. After the administration of fenofibrate nanocrystals of different sizes and evaluating 
the plasma concentration of the API, nanocrystals of 140 nm in size were selected as the most 
effective formulation. The plasma-time curve showed that fenofibrate-loaded nanocrystals of 140 
nm had the best bioavailability, with AUC of 34.532 (µg/ml∗h) and Cmax of 6.511, and represented 
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an effective hypolipidaemic formulation to lower the risk of atherosclerosis compared with the 
pure, crystalline form of fenofibrate with low solubility. Comparing the PK parameters of 
nanocrystal and liposomal formulations at the same administration dose (2.1 mg/kg), Soluthin S 90-
type liposomes showed a remarkably significant increase (P<0.05) in AUC and Cmax (Anhalt 2012), 
and it could therefore be concluded that the liposome formulation – and specifically Soluthin S 90-
type liposomes –have the ability to significantly increase fenofibrate bioavailability and absorption. 
Although the nanocrystals and liposomes were prepared to almost the same size range, the 
composition of each formulation was different and this could explain the higher bioavailability of 
the Soluthin S 90 liposomes. Liposomes are a type of lipid-based formulation that is mostly 
composed of membrane lipids with hydrophobic head and hydrophilic tails. Therefore, the lipid 
carrier, by forming chylomicrons, could increase the lymphatic transport of fenofibrate (Hu et al. 
2004). For fenofibrate, with a log P value of about 5.24, lymphatic absorption represents an 
additional method of fenofibrate transport and is a suitable lymphatic model for further studies to 
investigate the lymphatic transport of fenofibrate (Hu et al. 2011; Chakraborty et al. 2009). Another 
explanation for the increased AUC and Cmax of Soluthin S 90 liposomes may be their composition 
(Table 14), which was briefly described above. 
 
3.8.1 In vitro and in vivo correlation 
Although previous studies on the effect of gelatine on the stability of the oral liposomal 
formulations demonstrated that gelatine may increase the stability of formulations by increasing the 
viscosity inside and outside the liposomes, thereby improving bioavailability (Pantze et al. 2014), 
the in vitro lipolysis model in this study demonstrated no significant difference in the formulations 
in the presence and absence of gelatine, which strongly correlates with the data obtained from the in 
vivo experiments. 
Even though the fenofibrate release profile (%) showed no significant difference across all 
formulations, the in vivo results exhibited higher bioavailability for the Soluthin S 90-prepared 
liposomes compared with the EPC liposomes. Nevertheless, the NaOH titration profile showed that 
more FAs were released from S 90 formulations in 1 hour of lipolysis, which this FA titration 
reflects the formulation digestion. NaOH titration showed the results from the beginning of the 
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intestinal part (time 0), while the fenofibrate release profile (%) showed the amount of drug 
released after 5 minutes. At the start of pancreatin exposure to lipid-based formulations, digestion is 
rapid; however, as digestion proceeds and more FAs are released, the capacity of pancreatin for 
digestion decreases, and drug release is limited by this factor. Thus, the first minutes of sample 
contact with the intestinal environment are highly critical in term of drug release. 
 Moreover, the in vitro lipolysis model assessed the activity in the intestinal compartment, and not 
in the gastric part. Of course, lipid digestion mainly occurs in the intestine, although the gastric 
compartment – due to its low pH and presence of gastric lipolysis enzyme – could efficiently 
initiate and affect lipid digestion and, therefore, absorption. Another explanation for the lack of 
correlation between the in vitro and in vivo models may be the duration of the in vitro lipolysis 
experiments. The in vitro model ran for 1 hour while, in the in vivo PK studies, rats were under 
investigation for about 9 hours, and most of the important pharmacokinetic occurrences were 
observed after 1 hour. This suggests that further studies of more than 1 hour are required to clarify 
the findings of the in vitro studies.  
In this study, the presence and absence of gelatine in the in vitro rat lipolysis model correlated with 
the results of the in vivo pharmacokinetic studies, and the data on NaOH titration, corresponding 
with digestion and FA release, almost correlated with the in vivo plasma concentration. However, in 
terms of drug solubilisation, no significant correlation was observed between the in vitro and in vivo 
studies, and this was particularly the case with the in vitro lipolysis model. The biological 
environment of the gastrointestinal tract is highly complex with many unknown parameters that can 
affect the process of digestion and absorption, thus explaining why no suitable model for oral 
digestion has been established to date. This study strongly supports the construction of a more 
precise in vitro model for LBFs to obtain further correlation between drug solubilisation profiles 
from in vitro lipolysis models and in vivo pharmacokinetic profiles. The suggested model should 
include the gastric simulation model as well as the intestinal part from the beginning of the 
experiment (time 0), as the first minutes of sample exposure are critical for evaluating formulation 
digestion, and hence API release.  
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4.1 Summary and Conclusion 
Many new drug candidates show relatively low absorption due to their poor solubility in water. It 
remains challenging to formulate these poorly water-soluble drugs (PWSDs), although lipid-based 
drug delivery systems (LbDDS) represent the most successful strategy to date for formulating APIs 
with low solubility for oral delivery purposes. Among the different types of LbDDS, liposomes are 
used as drug delivery systems because of their advantageous characteristics such as flexibility, 
biocompatibility, biodegradability, increased drug therapeutic index and efficacy, increased stability 
of entrapped drug, reduced side effects, sustained release and drug reservoir properties. 
This thesis investigates the biopharmaceutical knowledge of different liposomal formulations 
obtained using two different phosphatidylcholines (EPC and S 90) in the present and absence of 
gelatine. The study aimed to characterize the oral lipid-based formulations in terms of 
physiochemical features, X-ray diffraction, dissolution, in vitro lipolysis and in vivo 
pharmacokinetic studies. The results and conclusions are summarized below. 
Liposomal formulations were prepared using different methods and were based on particle size and 
reproducibility of the method. Dual asymmetric centrifugation (DAC) and probe sonication were 
chosen as experimental methods to prepare fenofibrate-loaded liposomes. The prepared liposomes 
were used to investigate the physical features of vesicular phospholipid gels (VPGs) and the light-
scattering assessed the size and polydispersity of the in range and homogenous liposomes. 
Cryo_EM was carried out to evaluate the effect of gelatine on the vesicular liposomes, and the 
obtained images showed no significant difference in the features of the prepared liposomes. 
Fenofibrate-loaded liposomes had remarkably high entrapment efficiency (95%–99%), which was 
expected given that fenofibrate has a high lipophilic affinity and was placed within lipid-structured 
liposomes. 
The formation of crystalline fenofibrate was evaluated using X-ray powder diffraction (XRPD) 
experiments and the obtained diagrams showed no sign of the presence of crystalline fenofibrate in 
either gelatine-based formulations or those with the high concentrations of fenofibrate. This implies 
that the dissolution and digestion of liposomal formulations is not restricted by crystalline 
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fenofibrate. Next, dissolution behaviour of the samples was evaluated in a paddle model. The 
release of liposome from semi-solid formulations was assessed, and the results showed a negative 
correlation between the rate of liposome release and gelatine concentration. As gelatine occupies 
some volume during liposome preparation, the number of released liposomes from the formulation 
was relatively lower for gelatine-loaded formulations. The USP II model was also used to evaluate 
the release of fenofibrate from the liposomes using two different biorelevant media: Fasted state-
simulated intestinal fluid (FaSSIF), with a pH of 6.5, and fasted state-simulated gastric fluid 
(FaSSGF), with a pH of 1.6. In both media, non-gelatine-containing formulations released 
fenofibrate faster, and after the first 30 minutes, approximately 80% and after 1 hour more than 
95% of loaded drug was released, whereas gelatine-containing formulations released more than 
95% of fenofibrate after 2 hours. The stability of the different formulations was assessed for 3 
months at two different temperature conditions (room temperature and refrigerated), and all 
formulations showed relative stability in terms of size, PDI, and entrapment efficiency. 
The prepared liposomes were used in a dynamic in vitro lipolysis model to study the digestion and 
solubilisation of the drug formulations in biorelevant media simulating the gastrointestinal 
environment. As studies in rats were intended, the lipolysis model was established according to rat 
physiology and consisted of gastric and intestinal compartments. The release profile of fenofibrate 
for all liposomal formulations showed a general increasing trend (regardless of the type of 
phosphatidylcholine and amount of gelatine) towards the release of fenofibrate from the 
formulations in the aqueous phase, as digestion continued over time. There was no significant 
difference between the different types of prepared formulations in the release profile (%) of 
fenofibrate from liposomes into the aqueous phase of the lipolysis environment. Nevertheless, 
NaOH titration of the lipolysis model showed that the stoichiometric titration of Soluthin S 90-
prepared liposomes was higher than that of the other formulations but significantly (p<0.05) lower 
for the SPC-liposomes, indicating that more FAs were released upon digestion. 
For the in vivo studies, EPC and S 90 liposomes were administrated orally to fasted rats for 
pharmacokinetic characterization. These in vivo studies demonstrated that Soluthin S 90 
formulations, regardless of the presence or absence of gelatine, showed significantly higher 
(p<0.01) PK parameters in terms of AUC and Cmax. All formulations showed a similar Tmax, and the 
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presence or absence of gelatine had no significant effect on AUC, Cmax or Tmax for both EPC- and 
Soluthin S 90-type liposomal formulations. 
In this study, the absence and presence of gelatine in the in vitro rat lipolysis model correlated with 
the results of the in vivo pharmacokinetic studies, and the data from the NaOH titration, 
corresponding with the digestion and FA release, virtually correlated with the in vivo plasma 
concentration. However, in term of the drug solubilisation profile, no significant correlation was 
observed between the in vitro and in vivo studies, particularly in the case of the in vitro lipolysis 
model. 
In conclusion, the addition of gelatine, a natural substance, did not have a significant effect on 
pharmacokinetic parameters and, therefore, the absorption and bioavailability of liposomal 
formulations. The new phosphatidylcholine mixture, Soluthin S 90, strongly improved the 
absorption and bioavailability of fenofibrate-loaded liposomes. Further studies should be performed 
to investigate the effect of fenofibrate-loaded liposomes prepared by Soluthin S 90 on the intestinal 
permeability of the API and solubilisation capacity of the formulations in an in vitro lipolysis model 
combined with an absorption step. It is also recommended to combine the formulation with 
different surfactants to choose the optimal formulation. In addition, it is necessary to examine the 
bioavailability of different PWSDs formulated in Soluthin S 90 liposomes to elucidate the 
pharmacokinetic effect of such a formulation. 
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API Active pharmaceutical ingredient 
AUC Area under curve 
BBBA 4-bromobenzeneboronic acid 
BCS Biopharmaceutics classification system  
Cmax Maximal plasma concentration 
CMC Critical micellar concentration 
Cryo_EM Cryogenic electron microscopy 
DAC Dual asymmetric centrifugation 
DDS Drug delivery system 
DLS Dynamic light scattering  
FA Fatty acid 
FaSSGF Fasted state-simulated gastric fluid 
FaSSIF Fasted state-simulated intestinal fluid 
FDA The food and drug administration 
FF Fenofibrate 
FFA Fenofibric acid 
Gel Gelatine 
GI Gastro-intestinal 
GIT Gastro-intestinal tract 
HPLC High performance liquid chromatography 
HDL High-density lipoprotein 
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IV Intravenous 
IVIVC In vitro-in vivo correlation 
kcps Kilo counts per second 
LbDDS Lipid based drug delivery system 
LDL low-density lipoprotein 
MLVs Multilamellar vesicles 
NCE New chemical entity 
NEHI New England healthcare institute  
NLC Nanostructured lipid carrier 
ODD Oral drug delivery  
O/W Oil in water 
Ph.Eur. European pharmacopia 
PBS Phosphate buffered saline 
PDI  Polydispersity index 
QC Quality control 
SEM Standard error mean 
SIF Simulated intestinal fluid 
TBU Tributyrin units 
TG Triglyceride 
Tmax Time required for maximal plasma concentration  
USP United states pharmacopeia 
VLDL Very low-density lipoprotein 
VPGs Vesicular phospholipid gels 
XRPD X-ray powder diffraction 
 
